%PDF-1.3
%âãÏÓ
1 0 obj
<<
/Length 10494
>>
stream
/GS0 gs
q
0 0.701 595 793 re
W n
1 g
0 793.701 0 0 re
f
Q
/GS0 gs
/GS2 gs
q
0 0 0 0 k
42.52 51.024 510.236 657.638 re
f
527.244 18.126 25.512 16.673 re
f
BT
/F0 1 Tf
8 0 0 8 544.7559 19.8606 Tm
0 Tr
0 0 0 1 k
(80)Tj
ET
0 0 0 0 k
42.52 51.024 510.236 439.37 re
f
BT
/F1 1 Tf
8.5 0 0 8.5 42.5197 483.9609 Tm
0 0 0 1 k
-0.0002 Tc
(Resumen)Tj
ET
BT
/F2 1 Tf
8.5 0 0 8.5 53.8583 464.9609 Tm
(Objetivo:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 95.4087 464.9609 Tm
-0.0001 Tc
0.0699 Tw
(Describir el caso de una paciente diagnosticada de)Tj
-6.22224 -1.11765 TD
0 Tc
0.186 Tw
(glomerulonefritis membranosa y neutropenia no central autoin-)Tj
-0.0001 Tc
0.0943 Tw
(mune en tratamiento con ciclosporina, que desarroll\227 un cuadro)'
0 -1.11764 TD
0 Tw
(de cefalea intensa e incapacitante. )Tj
ET
BT
/F2 1 Tf
8.5 0 0 8.5 53.8583 426.9609 Tm
-0.0002 Tc
0.0044 Tw
(Descripci\227n del caso: )Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 146.5926 426.9609 Tm
-0.0001 Tc
0.0039 Tw
(Paciente de 66 a\226os de edad, sin his)Tj
15.80279 0 TD
0 Tc
(-)Tj
-28.04666 -1.11765 TD
0.021 Tw
(toria de cefaleas ni de reacciones adversas a medicamentos, diag-)Tj
0 -1.11764 TD
-0.027 Tw
(nosticada de glomerulonefritis membranosa y neutropenia no cen-)Tj
0 -1.11765 TD
-0.0001 Tc
0.0934 Tw
(tral autoinmune. Se inici\227 ciclosporina A neoral a dosis de unos)Tj
0.0814 Tw
(2,5 mg/kg/24 h (100 mg/12 h), con niveles de ciclosporina A,)'
0 -1.11764 TD
-0.0161 Tw
(en sangre total, dentro del \207mbito terap\216utico. La paciente refiri\227,)Tj
0 -1.11765 TD
0 Tc
0.075 Tw
(5 d\222as despu\216s, un cuadro de cefalea holocraneal intensa e inca-)Tj
-0.0001 Tc
0.0992 Tw
(pacitante. La tomograf\222a computerizada craneal fue normal y se)'
0 -1.11764 TD
0.0815 Tw
(descartaron otras causas de cefalea, que s\227lo desapareci\227 con la)Tj
0 -1.11765 TD
0 Tw
(supresi\227n de la ciclosporina. )Tj
ET
BT
/F2 1 Tf
8.5 0 0 8.5 53.8583 331.9609 Tm
-0.0002 Tc
(Comentario:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 109.8362 331.9609 Tm
0 Tc
0.147 Tw
(La cefalea intensa es un efecto adverso infre-)Tj
-7.91959 -1.11764 TD
-0.0001 Tc
0.0394 Tw
(cuente de la ciclosporina que es importante conocer porque pue)Tj
28.04666 0 TD
0 Tc
(-)Tj
-28.04666 -1.11765 TD
-0.0001 Tc
-0.0141 Tw
(de comprometer la adherencia al tratamiento y puede hacer nece)Tj
28.04666 0 TD
0 Tc
(-)Tj
-28.04666 -1.11765 TD
-0.0001 Tc
0.6091 Tw
(saria la suspensi\227n del f\207rmaco. La imputabilidad de la)Tj
0.1481 Tw
(ciclosporina con este efecto neurot\227xico se analiz\227 a trav\216s del)'
0 -1.11764 TD
0.0037 Tw
(m\216todo de estimaci\227n de la probabilidad de reacciones adversas a)Tj
0.059 Tw
(medicamentos de Naranjo, obteni\216ndose una relaci\227n de causali)'
28.04665 0.00001 TD
0 Tc
(-)Tj
-28.04665 -1.11766 TD
-0.0002 Tc
0 Tw
(dad de )Tj
ET
BT
/F4 1 Tf
8.5 0 0 8.5 69.3706 265.4609 Tm
(probable)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 102.8498 265.4609 Tm
0 Tc
(.)Tj
ET
BT
/F1 1 Tf
8.5 0 0 8.5 42.5197 246.4609 Tm
-0.0001 Tc
(Palabras clave:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 112.8813 246.4609 Tm
(Ciclosporina. Cefalea. Reacci\227n adversa.)Tj
ET
BT
/F1 1 Tf
8.5 0 0 8.5 42.5197 208.4609 Tm
(Summary)Tj
ET
BT
/F2 1 Tf
8.5 0 0 8.5 53.8583 189.4609 Tm
-0.0002 Tc
(Objective:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 100.4033 189.4609 Tm
-0.0001 Tc
0.1978 Tw
(To report the case of a patient diagnosed with)Tj
-6.80983 -1.11765 TD
0.4185 Tw
(membranous glomerulonephritis and autoimmune non-central)Tj
0 -1.11764 TD
0.3089 Tw
(neutropenia under treatment with cyclosporin who developed)Tj
0 Tw
(severe, disabling headache. )'
ET
BT
/F2 1 Tf
8.5 0 0 8.5 323.1496 483.9609 Tm
-0.0205 Tc
0.1676 Tw
(Case report:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 378.493 483.9609 Tm
-0.0181 Tc
0.1479 Tw
(A 66-year-old female patient with no history of)Tj
-7.84494 -1.11765 TD
-0.018 Tc
0.169 Tw
(headache or adverse drug reactions was diagnosed with membra-)Tj
0 -1.11764 TD
-0.0181 Tc
0.1141 Tw
(nous glomerulonephritis and autoimmune non-central neutropenia.)Tj
0 -1.11765 TD
(Neoral)Tj
4.25 0 0 4.25 335.3702 458.6484 Tm
0 Tc
<A8>Tj
8.5 0 0 8.5 341.8586 455.4609 Tm
-0.0181 Tc
0.0906 Tw
((cyclosporin A) was initiated at a dose of 2.5 mg/kg/24 h)Tj
-3.53501 -1.11765 TD
-0.018 Tc
-0.01 Tw
((100 mg/12 h), with whole blood cyclosporin levels within the thera-)Tj
0 -1.11764 TD
-0.0181 Tc
0.1158 Tw
(peutic range. After 5 days the patient reported holocranial severe,)Tj
0 -1.11765 TD
0.0145 Tw
(disabling headache. A cranial CT scan was normal and other heada)Tj
28.04666 0 TD
0 Tc
(-)Tj
-28.04666 -1.11765 TD
-0.0181 Tc
0.143 Tw
(che causes were also ruled out; her headache subsided only upon)Tj
0 -1.11764 TD
0 Tw
(cyclosporin discontinuation. )Tj
ET
BT
/F2 1 Tf
8.5 0 0 8.5 323.1496 398.4609 Tm
-0.0002 Tc
(Comment:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 369.9112 398.4609 Tm
-0.0001 Tc
0.0827 Tw
(Severe headache is an uncommon adverse effect)Tj
-6.83532 -1.11765 TD
0 Tc
-0.023 Tw
(of cyclosporin whose recognition is relevant, since it may compro-)Tj
0 -1.11764 TD
-0.0001 Tc
-0.0245 Tw
(mise therapy compliance and require the drug  to be discontinued.)Tj
0 -1.11765 TD
0.2818 Tw
(The attribution of cyclosporin with this neurotoxic effect was)Tj
T*
0 Tc
0.013 Tw
(analyzed using Naranjo\325s probability estimation method for adver-)Tj
0 -1.11764 TD
-0.0001 Tc
0.2142 Tw
(se drug reactions, which resulted in causality being considered)Tj
ET
BT
/F4 1 Tf
8.5 0 0 8.5 311.811 341.4609 Tm
-0.0002 Tc
(probable.)Tj
ET
BT
/F1 1 Tf
8.5 0 0 8.5 311.811 322.4609 Tm
0 Tw
(Key words:)Tj
ET
BT
/F3 1 Tf
8.5 0 0 8.5 362.9667 322.4609 Tm
-0.0001 Tc
(Cyclosporin. )Tj
5.73852 0 TD
0 Tc
(H)Tj
0.79981 0 TD
-0.0001 Tc
(eadache. )Tj
4.13916 0 TD
0 Tc
(A)Tj
0.71997 0 TD
-0.0001 Tc
(dverse reaction.)Tj
ET
0 J 0 j 0.4 i 10 M []0 d 0.667 w 
0 0 0 1 K
311.811 310.628 m
552.756 310.628 l
S
311.811 309.294 m
552.756 309.294 l
S
BT
/F2 1 Tf
10.5 0 0 10.5 311.811 241.9609 Tm
-0.0002 Tc
(INTRODUCCI\356N)Tj
ET
BT
/F0 1 Tf
10.5 0 0 10.5 323.1496 218.9609 Tm
0 Tc
0.118 Tw
[(La ciclosporina es un polip\216ptido de 1)37(1 amino\207cidos)]TJ
-1.07986 -1.09523 TD
-0.0001 Tc
0.1411 Tw
(obtenido a partir del hongo )Tj
ET
BT
/F5 1 Tf
10.5 0 0 10.5 435.5611 207.4609 Tm
0 Tc
(T)Tj
0.46411 0.00001 TD
-0.0001 Tc
(olypocladium inflatum. )Tj
ET
BT
/F0 1 Tf
10.5 0 0 10.5 543.4249 207.4609 Tm
-0.0003 Tc
(El)Tj
-22.05847 -1.09524 TD
0 Tc
0.106 Tw
(mecanismo de acci\227n consiste en la formaci\227n de com-)Tj
T*
0.086 Tw
[(plejos con la ciclofilina intracelular)40(, que se unen e inhi-)]TJ
0 -1.09523 TD
-0.0001 Tc
0.0325 Tw
(ben la calcineurina, lo que evita la activaci\227n de factores)Tj
0 -1.09524 TD
0.1011 Tw
(nucleares involucrados en la transcripci\227n de genes que)Tj
0 -1.09523 TD
0.0227 Tw
(codifican varias citocinas incluyendo la IL-2 y el interfe)Tj
22.61439 0.00001 TD
0 Tc
(-)Tj
-22.61439 -1.09525 TD
-0.0001 Tc
0.0139 Tw
(r\227n-gamma. El resultado final es la falta de activaci\227n de)Tj
0 -1.09524 TD
0.1154 Tw
(las c\216lulas T y de las respuestas inmunes mediadas por)Tj
0 -1.09523 TD
0.02 Tw
(estas c\216lulas. Ha sido utilizado con \216xito para prevenir el)Tj
0 -1.09524 TD
0.0422 Tw
(rechazo de \227r)Tj
5.45126 0.00001 TD
(ganos trasplantados, en el tratamiento de la)Tj
-5.45126 -1.09525 TD
0.0289 Tw
(diabetes mellitus tipo I, en las glomerulopat\222as, as\222 como)Tj
0 -1.09523 TD
0.0215 Tw
(en otras enfermedades autoinmunes como la uve\222tis idio)Tj
22.61437 0.00001 TD
0 Tc
(-)Tj
-22.61437 -1.09525 TD
0.09 Tw
[(p\207tica, artritis reumatoide, s\222ndrome de Sj\232gren\325)55(s, mias-)]TJ
0 -1.09524 TD
-0.0001 Tc
0.0199 Tw
(tenia )Tj
ET
BT
/F5 1 Tf
10.5 0 0 10.5 335.0505 57.9609 Tm
(gravis,)Tj
ET
BT
/F0 1 Tf
10.5 0 0 10.5 366.7546 57.9609 Tm
(psoriasis, etc. (1,2). En Espa\226a es un f\207rma)Tj
17.38164 0.00001 TD
0 Tc
(-)Tj
ET
BT
/F6 1 Tf
18 0 0 18 104.4278 668.0061 Tm
0.0008 Tc
0 Tw
(Cefalea asociada a ciclosporina en un paciente con)Tj
4.13904 -1.11111 TD
0.001 Tc
(glomerulonefritis membranosa)Tj
ET
BT
/F0 1 Tf
12 0 0 12 83.0133 615.0061 Tm
-0.0001 Tc
(J. BORR\347S BLASCO, R. ENR\352QUEZ)Tj
6 0 0 6 272.0045 619.0686 Tm
0 Tc
(1)Tj
12 0 0 12 275.0045 615.0061 Tm
[(, F)80(. AMOR\356S AMOR\356S)]TJ
6 0 0 6 398.3795 619.0686 Tm
(1)Tj
12 0 0 12 401.3795 615.0061 Tm
[(, A. NA)129(V)129(ARRO RUIZ, )]TJ
-19.5083 -1.08334 TD
[(V)129(. CONESA GARC\352A)]TJ
6 0 0 6 277.3805 606.0686 Tm
(2)Tj
12 0 0 12 280.3805 602.0061 Tm
-0.0001 Tc
(, M. GONZ\347LEZ DELGADO)Tj
ET
BT
/F5 1 Tf
10.5 0 0 10.5 56.8415 577.5061 Tm
0 Tc
(Servicio de Farmacia. )Tj
5.25 0 0 5.25 153.0564 581.0686 Tm
(1)Tj
10.5 0 0 10.5 155.6814 577.5061 Tm
[(Secci\227n de Nefr)37(olog\222a. )]TJ
5.25 0 0 5.25 253.8523 581.0686 Tm
(2)Tj
10.5 0 0 10.5 256.4773 577.5061 Tm
-0.0001 Tc
(Secci\227n de Hematolog\222a. Hospital General Universitario de Elche.)Tj
2.25403 -1.09524 TD
(Alicante)Tj
ET
BT
/F3 1 Tf
7 0 0 7 42.5197 758.048 Tm
-0.0002 Tc
(1130-6343/2004/28/6/454)Tj
0 -0.99999 TD
0 Tc
(F)Tj
5.25 0 0 5.25 46.4384 751.048 Tm
-0.0001 Tc
(ARMACIA)Tj
7 0 0 7 73.1041 751.048 Tm
0 Tc
(H)Tj
5.25 0 0 5.25 78.7027 751.048 Tm
-0.0001 Tc
(OSPITALARIA)Tj
7 0 0 7 42.5197 744.048 Tm
-0.0002 Tc
(Copyright \251 2004 )Tj
8.45751 0.00001 TD
0 Tc
(A)Tj
5.25 0 0 5.25 106.7621 744.048 Tm
-0.0001 Tc
(R\347N)Tj
7 0 0 7 120.0952 744.048 Tm
0 Tc
(E)Tj
5.25 0 0 5.25 124.2942 744.048 Tm
-0.0001 Tc
(DICIONES)Tj
7 0 0 7 149.0689 744.048 Tm
-0.0002 Tc
(, S. L)Tj
2.39893 0.00001 TD
0 Tc
(.)Tj
ET
0 0 0 0 k
42.52 57.701 240.945 86.932 re
f
0.5 w 
42.52 113.189 m
283.465 113.189 l
S
BT
/F5 1 Tf
8 0 0 8 42.5197 104.4354 Tm
0 0 0 1 k
-0.0001 Tc
(Recibido: )Tj
ET
BT
/F0 1 Tf
8 0 0 8 75.6154 104.4354 Tm
(15-01-2004)Tj
ET
BT
/F5 1 Tf
8 0 0 8 42.5197 95.4354 Tm
(Aceptado: )Tj
ET
BT
/F0 1 Tf
8 0 0 8 77.3927 95.4354 Tm
(03-03-2004)Tj
ET
BT
/F5 1 Tf
8 0 0 8 42.5197 77.4354 Tm
-0.0151 Tc
0.138 Tw
(Correspondencia: )Tj
ET
BT
/F0 1 Tf
8 0 0 8 101.7909 77.4354 Tm
-0.0001 Tc
(Joaqu\222n Borr\207s Blasco. Servicio de Farmacia. Hospital)Tj
-7.4089 -1.125 TD
0.0199 Tc
-0.0043 Tw
(General Universitario. Cam\222 de L\325Almazara, 11. 03203 Elche. Alicante.)Tj
T*
0 Tc
0 Tw
[(e)-20(-)-20(mail: jborrasb@sefh.es)]TJ
ET
BT
/F3 1 Tf
7 0 0 7 492.2203 760.3819 Tm
(F)Tj
5.25 0 0 5.25 496.139 760.3819 Tm
-0.0001 Tc
(ARM)Tj
7 0 0 7 510.1014 760.3819 Tm
0 Tc
(H)Tj
5.25 0 0 5.25 515.7 760.3819 Tm
-0.0002 Tc
(OSP)Tj
7 0 0 7 528.4012 760.3819 Tm
-0.0001 Tc
((Madrid))Tj
-11.99562 -1 TD
0 Tc
[(Vol. 28. N.\241)-300(6, pp. 454-457, 2004)]TJ
ET
0 0 0 0.2 k
437.387 738.942 115.369 11.13 re
f
BT
/F2 1 Tf
7 0 0 7 443.4214 742.54 Tm
0 0 0 1 k
-0.0001 Tc
(COMUNICACIONES CORTAS)Tj
ET
Q
endstream
endobj
2 0 obj
<<
/SA false
/OPM 1
/Type/ExtGState
/OP false
>>
endobj
3 0 obj
<<
/SA false
/OPM 1
/Type/ExtGState
/OP true
>>
endobj
4 0 obj
<<
/Length 10431
>>
stream
/GS0 gs
q
0 0.701 595 793 re
W n
1 g
0 793.701 0 0 re
f
Q
/GS0 gs
/GS2 gs
0 0 0 0 k
42.52 51.024 510.236 657.638 re
f
q
BT
/F0 1 Tf
10.5 0 0 10.5 42.5197 701.4813 Tm
0 Tr
0 0 0 1 k
0.08 Tw
[(co autorizado para el tratamiento del trasplante de \227r)18(ga-)]TJ
0 -1.09524 TD
-0.0001 Tc
0.1299 Tw
(nos y de m\216dula \227sea, y en enfermedades autoinmunes)Tj
0 -1.09523 TD
0 Tc
0.03 Tw
(tales como uve\222tis end\227gena, psoriasis, s\222ndrome nefr\227ti-)Tj
0 -1.09524 TD
-0.0001 Tc
0 Tw
(co, artritis reumatoide y dermatitis at\227pica severa.)Tj
1.07987 -1.09524 TD
0.0897 Tw
(Los efectos adversos m\207s frecuentes son deterioro de)Tj
-1.07987 -1.09523 TD
0.3677 Tw
(la funci\227n renal y hep\207tica, hipertricosis, temblores,)Tj
0 -1.09524 TD
0 Tc
0.064 Tw
(hipertensi\227n arterial, hipertrofia gingival, trastornos gas-)Tj
0 -1.09523 TD
-0.0001 Tc
0.0291 Tw
(trointestinales y sensaci\227n de quemaz\227n en manos y pies)Tj
0 -1.09524 TD
0.0376 Tw
((3,4). Presentamos el caso de una paciente diagnosticada)Tj
T*
0 Tc
0.085 Tw
(de glomerulonefritis membranosa y neutropenia no cen-)Tj
0 -1.09523 TD
0.041 Tw
[(tral autoinmune en tratamiento con este inmunosupresor)40(,)]TJ
0 -1.09524 TD
-0.019 Tw
(que desarroll\227 un cuadro de cefalea intensa e incapacitan-)Tj
0 -1.09523 TD
-0.0001 Tc
0 Tw
(te. )Tj
ET
BT
/F2 1 Tf
10.5 0 0 10.5 42.5197 528.9813 Tm
(DESCRIPCI\356N DEL CASO )Tj
ET
BT
/F0 1 Tf
10.5 0 0 10.5 53.8583 505.9813 Tm
0 Tc
0.002 Tw
(Paciente de 66 a\226os de edad, que fue remitida por ede-)Tj
-1.07987 -1.09523 TD
-0.0001 Tc
-0.0054 Tw
(mas, que hab\222an aparecido 6 semanas antes, en miembros)Tj
0 -1.09524 TD
0 Tc
0.109 Tw
(inferiores; no refer\222a otra sintomatolog\222a. Como antece-)Tj
0 -1.09523 TD
-0.01 Tw
(dentes personales destacaba asma bronquial; no ten\222a his-)Tj
0 -1.09524 TD
-0.0001 Tc
0.023 Tw
(toria de cefaleas ni de reacciones adversas a medicamen)Tj
22.61438 0 TD
0 Tc
(-)Tj
-22.61438 -1.09524 TD
-0.0001 Tc
(tos.)Tj
1.07987 -1.09524 TD
0.3863 Tw
(Exploraci\227n f\222sica: afebril, tensi\227n arterial 120/80)Tj
-1.07987 -1.09524 TD
0 Tc
0.014 Tw
(mmHg, edemas con f\227vea hasta rodillas; el resto era nor-)Tj
-0.0001 Tc
0.0137 Tw
(mal. Las exploraciones complementarias revelaron: VSG)'
T*
0 Tc
0.105 Tw
[(127 mm/h, hemoglobina 1)37(1 g/dl, leucocitos 3.130/ mm)]TJ
5.25 0 0 5.25 280.8396 406.0438 Tm
(3)Tj
10.5 0 0 10.5 42.5197 390.9813 Tm
-0.0001 Tc
0.316 Tw
((vn 4.000-10.000), neutr\227filos 1.010 mm)Tj
5.25 0 0 5.25 227.8409 394.5438 Tm
0 Tc
(3)Tj
10.5 0 0 10.5 236.4086 390.9813 Tm
-0.0001 Tc
(\(vn 2.000-)Tj
-18.46561 -1.09524 TD
-0.0081 Tw
(7.200\), linfocitos 1.600 \(vn 1.500-4.500\), eosin\227filos 150)Tj
0.2073 Tw
((vn 40-500), monocitos 370 (vn 400-1.100); los CD4,)'
T*
0 Tc
0.057 Tw
(CD8, plaquetas y coagulaci\227n fueron normales. Coleste-)Tj
-0.0001 Tc
0.1016 Tw
(rol total 420 mg/dl (vn 92-220), triglic\216ridos 213 mg/dl)'
T*
0 Tc
0.039 Tw
((vn 40-150), prote\222nas totales 3,9 g/dl (vn 6,4-8,3), alb\234-)Tj
-0.0001 Tc
0.065 Tw
(mina 1,9 g/dl (vn 3,5-5,2); la urea, creatinina, iones y el)'
T*
0 Tc
-0.02 Tw
(resto de la bioqu\222mica elemental estaban dentro de la nor-)Tj
-0.0001 Tc
0.4727 Tw
(malidad. Los anticuerpos antigranulocito \(IgG+IgM,)'
0 -1.09523 TD
0.0636 Tw
(citometr\222a de flujo\) fueron positivos; IgG 151 mg/dl \(vn)Tj
0 -1.09525 TD
0 Tc
0.152 Tw
(800-1.800\). Las siguientes determinaciones fueron nor-)Tj
0 -1.09523 TD
-0.0001 Tc
0.0465 Tw
(males o negativas: IgA, IgM, C3, C4, factor reumatoide,)Tj
0 -1.09524 TD
0.1151 Tw
(ANA, anti-ADN, Ro, La, RNP)Tj
12.6797 0.00001 TD
(, anti-TPO y TSH. En el)Tj
-12.6797 -1.09525 TD
0.052 Tw
(proteinograma no hab\222a bandas monoclonales. Mantoux,)Tj
0 -1.09523 TD
0.2008 Tw
(RPR, serolog\222a para virus de la hepatitis B, C y VIH)Tj
0 -1.09524 TD
0 Tc
0.054 Tw
[(negativos. Orina: proteinuria 1)37(1 g/24 h \(patr\227n glomeru-)]TJ
-0.0001 Tc
0.248 Tw
(lar no selectivo por electroforesis de alta resoluci\227n\),)'
0 -1.09523 TD
0.1035 Tw
(sedimento: 6-8 hemat\222es/c, 8-10 leucocitos/c, cultivo de)Tj
0 -1.09524 TD
0 Tc
-0.016 Tw
(orina negativo. Los ri\226ones aparec\222an normales en la eco-)Tj
T*
0.07 Tw
(graf\222a abdominal. La radiograf\222a de t\227rax y el ECG fue-)Tj
0 -1.09523 TD
0.047 Tw
(ron normales. En la biopsia renal percut\207nea se observa-)Tj
0 -1.09524 TD
-0.0001 Tc
1.0161 Tw
(ron cambios compatibles con glomerulonefritis)Tj
0.1689 Tw
(membranosa. El tr\207nsito gastrointestinal, enema opaco,)'
0 -1.09523 TD
0.0292 Tw
(TC abd\227mino-p\216lvico y la punci\227n aspiraci\227n de m\216dula)Tj
0 -1.09524 TD
0 Tw
(\227sea no mostraron hallazgos relevantes.)Tj
1.07987 -1.09524 TD
-0.015 Tc
-0.017 Tw
(La enferma se diagnostic\227 de glomerulonefritis membra-)Tj
-1.07987 -1.09523 TD
-0.0151 Tc
0.0394 Tw
(nosa y neutropenia no central autoinmune y se inici\227 trata)Tj
22.61436 0.00001 TD
0 Tc
(-)Tj
-22.61436 -1.09525 TD
-0.0151 Tc
0.0164 Tw
(miento con restricci\227n hidrosalina, furosemida 40 mg/d vo,)Tj
0 -1.09524 TD
-0.015 Tc
-0.002 Tw
(losart\207n 25 mg/d vo, ranitidina 150 mg/d vo, \207cido acetilsa-)Tj
0 -1.09523 TD
-0.0151 Tc
0.0266 Tw
(lic\222lico 100 mg/d vo y simvastatina 10 mg/d vo; el losart\207n)Tj
25.64679 61.33333 TD
0.0763 Tw
(tuvo que suspenderse por hipotensi\227n y disminuci\227n de la)Tj
0 -1.09524 TD
0 Tw
(diuresis. )Tj
1.07986 -1.09523 TD
-0.0217 Tw
(Seis meses despu\216s persist\222an los edemas y la proteinuria)Tj
-1.07986 -1.09524 TD
-0.0246 Tw
(masiva; los neutr\227filos en las sucesivas revisiones oscilaban)Tj
0.092 Tw
(entre 930 y 2.000/mm)'
5.25 0 0 5.25 404.2924 659.0438 Tm
0 Tc
(3)Tj
10.5 0 0 10.5 406.8386 655.4813 Tm
-0.015 Tc
(. Se decidi\227 tratamiento inmunosu-)Tj
-9.05025 -1.09523 TD
0.014 Tw
(presor; comentadas con la paciente las alternativas terap\216u-)Tj
0 -1.09524 TD
-0.001 Tw
(ticas y dada su neutropenia de base, se opt\227 por iniciar tera-)Tj
0 -1.09523 TD
-0.0151 Tc
0.0114 Tw
(pia con ciclosporina A neoral a dosis de unos 2,5 mg/kg/24)Tj
0 -1.09524 TD
-0.0114 Tw
(h (100 mg/12 h). La paciente refiri\227, 5 d\222as despu\216s, cefalea)Tj
0.1451 Tw
(holocraneal intensa que aparec\222a a la hora y media de la)'
0 -1.09523 TD
0.1429 Tw
(toma de ciclosporina, y que se aliviaba parcialmente con)Tj
0 -1.09524 TD
0.071 Tw
(paracetamol. La enferma no ten\222a antecedentes de cefalea.)Tj
T*
-0.015 Tc
0.019 Tw
(No hab\222a signos de focalidad neurol\227gica y los pulsos tem-)Tj
0 -1.09523 TD
-0.0151 Tc
0.195 Tw
(porales eran patentes. Los niveles de ciclosporina A, en)Tj
0 -1.09524 TD
0.0065 Tw
(sangre total, fueron 150,39 ng/ml \(rango considerado como)Tj
0 -1.09523 TD
0.1352 Tw
(terap\216utico 120-200\), magnesio s\216rico 2,2 mg/dl \(vn 1,9-)Tj
0 -1.09525 TD
0.2122 Tw
(2,5\); el resto de los par\207metros anal\222ticos no mostraban)Tj
0 -1.09523 TD
0.0545 Tw
(cambios sustanciales. En la TC craneal no se evidenciaron)Tj
0 Tw
(alteraciones. )'
1.46636 -1.09524 TD
0.1515 Tw
(La dosis de ciclosporina se redujo progresivamente a)Tj
-1.46636 -1.09524 TD
0.0783 Tw
(1,25 mg/kg/24 h (50 mg/12 h) y los niveles disminuyeron)Tj
0.1908 Tw
(hasta 62,9 ng/ml, pese a lo cual persist\222a la cefalea que)'
0.081 Tw
(interfer\222a con su actividad normal. Se baraj\227 la utilizaci\227n)'
T*
-0.015 Tc
0.069 Tw
(de otros analg\216sicos, pero a petici\227n de la enferma se sus-)Tj
-0.0151 Tc
0.0551 Tw
(pendi\227 la ciclosporina a los 16 d\222as de su inicio; la cefalea)'
0 Tw
(desapareci\227 3-4 d\222as despu\216s sin recurrir posteriormente. )'
ET
BT
/F2 1 Tf
10.5 0 0 10.5 311.811 379.4813 Tm
-0.0002 Tc
(COMENT)Tj
4.5603 0 TD
-0.0001 Tc
(ARIO)Tj
ET
BT
/F0 1 Tf
10.5 0 0 10.5 323.1496 356.4813 Tm
0 Tc
0.118 Tw
[(La ciclosporina es un polip\216ptido de 1)37(1 amino\207cidos)]TJ
-1.07986 -1.09524 TD
-0.0001 Tc
0.0907 Tw
(de naturaleza lip\227fila, que presenta concentraciones ele)Tj
22.61436 0 TD
0 Tc
(-)Tj
-22.61436 -1.09524 TD
-0.0001 Tc
0.02 Tw
(vadas a nivel del tejido adiposo y se une en un 80% a las)Tj
0.0893 Tw
(lipoprote\222nas, pero con una pobre y err\207tica penetraci\227n)'
T*
0 Tc
0.065 Tw
(al sistema nervioso central. La ciclosporina es metaboli-)Tj
-0.0001 Tc
0.1039 Tw
(zada por el citocromo P450 3 A, con excreci\227n biliar y)'
0 -1.09523 TD
0.2363 Tw
(recirculaci\227n enterohep\207tica. Los efectos adversos son)Tj
0 -1.09525 TD
0.1057 Tw
(generalmente dependientes de la dosis y responden a la)Tj
0 -1.09523 TD
0.1505 Tw
(disminuci\227n de la misma, siendo los m\207s frecuentes el)Tj
0 -1.09524 TD
0.2281 Tw
(deterioro de la funci\227n renal y hep\207tica, hipertricosis,)Tj
T*
0 Tc
-0.008 Tw
(temblores, hipertensi\227n arterial, hipertrofia gingival, tras-)Tj
0 -1.09523 TD
-0.0001 Tc
0.441 Tw
(tornos gastrointestinales \(n\207usea, v\227mitos, diarrea y)Tj
0 -1.09524 TD
0.0809 Tw
(malestar digestivo\), sensaci\227n de quemaz\227n en manos y)Tj
0.1829 Tw
(pies, y alteraciones electrol\222ticas como hipercaliemia e)'
0 -1.09523 TD
(hipomagnesemia.)Tj
1.31361 -1.09524 TD
-0.015 Tc
-0.001 Tw
(Pese a su irregular paso a trav\216s de la barrera hematoen-)Tj
-1.31361 -1.09524 TD
-0.0151 Tc
0.031 Tw
(cef\207lica, la ciclosporina es un f\207rmaco que provoca efectos)Tj
0 -1.09523 TD
0.1228 Tw
(secundarios neurol\227gicos en aproximadamente el 40% de)Tj
0 -1.09524 TD
0.1394 Tw
(pacientes (5). El m\207s frecuente es el temblor)Tj
18.02931 0.00001 TD
(, tambi\216n se)Tj
-18.02931 -1.09525 TD
0.0291 Tw
(han descrito reacciones neurot\227xicas leves como agitaci\227n,)Tj
0 -1.09523 TD
0.0532 Tw
(insomnio, ansiedad y amnesia. Como efectos neurot\227xicos)Tj
0 -1.09524 TD
0.2679 Tw
(severos asociados a la ciclosporina se han comunicado)Tj
T*
-0.015 Tc
0.085 Tw
(casos de confusi\227n, desorientaci\227n, alucinaciones, convul-)Tj
0 -1.09523 TD
-0.0151 Tc
0.0079 Tw
(siones, leucoencefalopat\222a posterior)Tj
13.73425 0.00001 TD
(, neuropat\222a perif\216rica y)Tj
-13.73425 -1.09525 TD
0.0939 Tw
(s\222ndromes extrapiramidales (6). Se han descrito diferentes)Tj
0 -1.09524 TD
0.1816 Tw
(factores de riesgo que pueden favorecer el desarrollo de)Tj
0 -1.09523 TD
0.116 Tw
(neurotoxicidad, entre los que se encuentra la hipertensi\227n)Tj
7 0 0 7 42.5197 744.001 Tm
0 Tc
0 Tw
(Vol. 28. N.)Tj
4.47167 0.00001 TD
[<A1>-250(6, 2004)-4754(CEFALEA ASOCIADA A CICLOSPORINA EN UN PACIENTE CON GLOMERULONEFRITIS MEMBRANOSA)]TJ
8 0 0 8 540.7559 744.001 Tm
(455)Tj
ET
0 0 0 0 k
42.744 18.126 25.512 15.007 re
f
BT
/F0 1 Tf
8 0 0 8 42.7441 19.8606 Tm
0 0 0 1 k
(83)Tj
ET
Q
endstream
endobj
5 0 obj
<<
/Length 10077
>>
stream
/GS0 gs
q
0 0.701 595 793 re
W n
1 g
0 793.701 0 0 re
f
Q
/GS0 gs
/GS2 gs
0 0 0 0 k
42.52 51.024 510.236 657.638 re
f
q
BT
/F0 1 Tf
10.5 0 0 10.5 42.5197 701.4813 Tm
0 Tr
0 0 0 1 k
-0.0151 Tc
-0.0145 Tw
(arterial, la hipomagnesemia, y la hipocolesterolemia (6). En)Tj
0 -1.09524 TD
-0.015 Tc
0.097 Tw
(la paciente que describimos la tensi\227n arterial estaba con-)Tj
0 -1.09523 TD
-0.0151 Tc
0.1212 Tw
(trolada, el magnesio s\216rico era normal y el colesterol por)Tj
0 -1.09524 TD
0 Tw
(encima del rango habitual.)Tj
1.07987 -1.09524 TD
-0.0001 Tc
0.0616 Tw
(La cefalea de intensidad leve puede aparecer hasta en)Tj
-1.07987 -1.09523 TD
0.005 Tw
(un 20-37% de los pacientes tratados con ciclosporina (7).)Tj
0 -1.09524 TD
0 Tc
-0.02 Tw
[(Sin embar)18(go, la cefalea intensa e incapacitante que obliga)]TJ
0 -1.09523 TD
-0.014 Tw
(a disminuir su dosis o suspenderla tiene una baja frecuen-)Tj
0 -1.09524 TD
-0.0001 Tc
0.1095 Tw
(cia (8) y se ha descrito tanto en pacientes trasplantados)Tj
T*
0 Tc
-0.008 Tw
[(\(9,10\) como en no trasplantados \(1)37(1\). En la tabla I se pre-)]TJ
0 -1.09523 TD
0.002 Tw
(sentan los casos cl\222nicos de cefalea intensa e incapacitan-)Tj
0 -1.09524 TD
-0.0001 Tc
0 Tw
(te descritos en la literatura m\216dica (9,12,13).)Tj
1.07987 -1.09524 TD
-0.0151 Tc
0.2501 Tw
(El mecanismo patog\216nico de la cefalea inducida por)Tj
-1.07987 -1.09523 TD
0.0624 Tw
(ciclosporina es desconocido y no se encuentra relacionado)Tj
0 -1.09524 TD
-0.015 Tc
0.03 Tw
(con niveles sangu\222neos t\227xicos. Se postula que la ciclospo-)Tj
0 -1.09523 TD
-0.0151 Tc
0.0999 Tw
(rina podr\222a tener un efecto vasoactivo y de proagregaci\227n)Tj
0 -1.09525 TD
-0.0203 Tw
(plaquetaria que disminuir\222a el flujo sangu\222neo cerebral (14).)Tj
0 -1.09523 TD
-0.015 Tc
0.103 Tw
(La ciclosporina incrementa el ADP que induce la agrega-)Tj
-0.0151 Tc
0.2669 Tw
(ci\227n plaquetaria y libera tromboxano A)'
5.25 0 0 5.25 215.8554 492.3814 Tm
0 Tc
(2)Tj
10.5 0 0 10.5 218.4016 494.4814 Tm
-0.0151 Tc
(, act\234a adem\207s)Tj
-16.75066 -1.09524 TD
0.1119 Tw
(sobre las c\216lulas endoteliales inhibiendo la producci\227n de)Tj
T*
-0.015 Tc
-0.005 Tw
(prostaciclina. Como consecuencia de estos efectos, se redu-)Tj
-0.0151 Tc
0.0447 Tw
(cir\222a el calibre arterial y el flujo sangu\222neo cerebral y renal)'
0 Tw
(en pacientes tratados con este inmunosupresor (15).)'
1.07987 -1.09524 TD
-0.0001 Tc
-0.0211 Tw
(La cefalea asociada a la administraci\227n de ciclosporina)Tj
-1.07987 -1.09524 TD
0.1128 Tw
(no responde a un tratamiento analg\216sico cl\207sico para el)Tj
-0.0232 Tw
(dolor de cabeza, ni al empleo de amitriptilina o verapami)'
22.61436 0 TD
0 Tc
(-)Tj
-22.61436 -1.09524 TD
0.014 Tw
(lo (6). Asimismo, tampoco parece que desarrolle toleran-)Tj
-0.0001 Tc
0.047 Tw
(cia contrariamente a lo descrito con otros f\207rmacos (16).)'
0.0724 Tw
(Gryn y cols., estudiaron el efecto del empleo de propra)'
22.61437 0 TD
0 Tc
(-)Tj
-22.61437 -1.09524 TD
-0.0001 Tc
0.0458 Tw
(nolol 20 mg/6-8 h en pacientes con cefalea asociada a la)Tj
0.1359 Tw
(administraci\227n de ciclosporina, desapareciendo el dolor)'
25.64679 32.85714 TD
0.049 Tw
(de cabeza en 4 de los 7 pacientes incluidos en el estudio)Tj
0 -1.09524 TD
0 Tc
0.025 Tw
[((10). Sin embar)18(go, este betabloqueante no ha sido efecti-)]TJ
0 -1.09523 TD
-0.0001 Tc
0.023 Tw
(vo en otras ocasiones (8,12). Parece que el sumatriptan o)Tj
0 -1.09524 TD
0 Tc
0.209 Tw
[(los er)18(gotam\222nicos son otras opciones terap\216uticas para)]TJ
-0.0001 Tc
0.2361 Tw
(aliviar la cefalea inducida por ciclosporina (8,12). En)'
0 -1.09523 TD
0.3124 Tw
(nuestra paciente, la existencia concomitante de asma)Tj
0 -1.09524 TD
0.1302 Tw
(bronquial contraindicaba el empleo de betabloqueantes;)Tj
0 -1.09523 TD
0 Tc
0.179 Tw
[(por otra parte el sumatriptan y la er)18(gotamina no est\207n)]TJ
0 -1.09524 TD
-0.008 Tw
(desprovistos de efectos adversos y por decisi\227n de la pro-)Tj
-0.0001 Tc
0 Tw
(pia enferma se suspendi\227 la ciclosporina.)'
1.07986 -1.09523 TD
0 Tc
0.026 Tw
(En el presente caso son varias las evidencias que indi-)Tj
-1.07986 -1.09524 TD
-0.0001 Tc
0.0183 Tw
(can la relaci\227n entre la ciclosporina y la cefalea intensa e)Tj
T*
0 Tc
0.115 Tw
[(incapacitante. En primer lugar)40(, existe una relaci\227n tem-)]TJ
0 -1.09523 TD
-0.0001 Tc
0.0223 Tw
(poral entre la aparici\227n de los s\222ntomas neurol\227gicos con)Tj
0 -1.09524 TD
0 Tc
0.003 Tw
[(el inicio de la terapia con ciclosporina. En segundo lugar)40(,)]TJ
0 -1.09523 TD
-0.009 Tw
(otras potenciales causas de cefalea se descartaron razona-)Tj
0 -1.09525 TD
-0.014 Tw
[(blemente. En tercer lugar)40(, cuando la dosis de ciclosporina)]TJ
0 -1.09523 TD
-0.0001 Tc
0.0708 Tw
(fue reducida a la mitad, la cefalea persisti\227 y no remiti\227)Tj
T*
0 Tc
0.18 Tw
[(hasta que se suspendi\227 el inmunosupresor)55(. Adem\207s, la)]TJ
0 -1.09524 TD
0.06 Tw
(ciclosporina fue el \234nico f\207rmaco que se a\226adi\227 al trata-)Tj
0 -1.09523 TD
-0.004 Tw
(miento de la paciente antes de que se desarrollar\207 la cefa-)Tj
0 -1.09524 TD
-0.0001 Tc
0.0051 Tw
(lea intensa e incapacitante. La imputabilidad de la ciclos)Tj
22.61439 0 TD
0 Tc
(-)Tj
-22.61439 -1.09524 TD
-0.0001 Tc
0.017 Tw
(porina con este efecto neurot\227xico se analiz\227 a trav\216s del)Tj
0.1486 Tw
(m\216todo de estimaci\227n de la probabilidad de reacciones)'
0.1086 Tw
(adversas a medicamentos de Naranjo, obteni\216ndose una)'
0 Tw
(relaci\227n de causalidad de probable (17).)'
1.07986 -1.09524 TD
0.0958 Tw
(Este caso ilustra un efecto adverso de la ciclosporina)Tj
-1.07986 -1.09524 TD
0.1961 Tw
(que es importante conocer por la repercusi\227n sobre la)Tj
0.0398 Tw
(calidad de vida que ocasiona, que puede comprometer la)'
0.0507 Tw
(adherencia al tratamiento y que puede hacer necesaria la)'
0 Tw
(suspensi\227n del f\207rmaco.)'
8 0 0 8 42.5197 744.001 Tm
0 Tc
(456)Tj
7 0 0 7 255.1593 744.001 Tm
-0.0001 Tc
(J. BORR\347S BLASCO ET AL.)Tj
34.0434 0.00001 TD
0 Tc
(F)Tj
5.25 0 0 5.25 497.3545 744.001 Tm
-0.0001 Tc
(ARM)Tj
7 0 0 7 511.0631 744.001 Tm
0 Tc
(H)Tj
5.25 0 0 5.25 516.1166 744.001 Tm
-0.0001 Tc
(OSP)Tj
7 0 0 7 527.4937 744.001 Tm
-0.0002 Tc
((Madrid))Tj
ET
0 0 0 0 k
527.244 18.126 25.512 16.673 re
f
BT
/F0 1 Tf
8 0 0 8 544.7559 19.8606 Tm
0 0 0 1 k
0 Tc
(84)Tj
ET
0 0 0 0 k
42.52 57.701 510.236 291.657 re
f
0 J 0 j 0.4 i 10 M []0 d 0.5 w 
0 0 0 1 K
42.52 316.176 m
552.756 316.176 l
S
BT
/F17 1 Tf
8.5 0 0 8.5 150.5656 320.6779 Tm
0 0 0 1 k
-0.0002 Tc
(Tabla I. )Tj
ET
BT
/F18 1 Tf
8.5 0 0 8.5 181.7412 320.6779 Tm
-0.0001 Tc
(Casos cl\222nicos de cefalea intensa e incapacitante descritos en la literatura)Tj
ET
BT
/F19 1 Tf
7.225 0 0 8.5 42.5197 306.6779 Tm
0 Tc
[(Referencia)-3946(Pacientes)-2034(Edad)-1626(Sexo (M/F))-2286(Diagn\227stico)-2672(Dosis)-4898(Niveles )-6267(Tratamiento)]TJ
33.06209 -1.17647 TD
-0.0001 Tc
(ciclosporina)Tj
7.12 0.00001 TD
(sangu\222neos)Tj
ET
42.52 282.176 m
552.756 282.176 l
S
BT
/F19 1 Tf
7.225 0 0 8.5 332.8353 286.6779 Tm
(ciclosporina)Tj
ET
BT
/F18 1 Tf
7.225 0 0 8.5 42.5197 272.6779 Tm
0 Tc
[(Steiger et al., )-4196(1)-4228(48)-4126(F)-4286(Trasplante)-3283(400 mg/d)-2952(Dentro del \207mbito)-1712(Mantuvo dosis de ciclosporina, siendo no)]TJ
0.5559 -1.17647 TD
-0.0001 Tc
(1994 (12))Tj
24.83441 0.00001 TD
(hep\207tico)Tj
14.5137 0.00001 TD
0 Tc
0.191 Tw
[(terap\216utico)-5212(efectivo el tratamiento con pizotifeno, propra)-1(-)]TJ
10.04408 -1.17648 TD
-0.0001 Tc
0 Tw
(nolol y amitriptilina. S\222 mejor\227 con sumatriptan )Tj
-39.86521 -1.17647 TD
0 Tc
[(2)-4228(59)-4126(F)-4286(Trasplante)-3284(400 mg/d)-2952(Dentro del \207mbito)-1712(Disminuy\227 la dosis a 350 mg/d, siendo no )]TJ
15.30742 -1.17647 TD
-0.0001 Tc
(hep\207tico)Tj
14.79178 0.00001 TD
(terap\216utico)Tj
10.04282 0.00001 TD
0.0947 Tw
(efectivo el tratamiento con analg\216sicos y ergo)Tj
20.06324 0.00001 TD
0 Tc
(-)Tj
-20.06324 -1.17649 TD
-0.0001 Tc
0 Tw
(tamina. S\222 mejor\227 con sumatriptan)Tj
-40.14202 -1.17647 TD
0 Tc
[(3)-4228(59)-4126(F)-4286(Trasplante )-3006(Disminuye)-2732(Dentro del \207mbito)-1712(Disminuy\227 la dosis a 125 mg/d, siendo efectivo)]TJ
15.30742 -1.17646 TD
[(hep\207tico)-4006(dosis inicial )-2065(terap\216utico)-5213(el tratamiento con paracode\222na)]TJ
ET
42.52 188.176 m
552.756 188.176 l
S
BT
/F18 1 Tf
7.225 0 0 8.5 281.3933 192.6779 Tm
-0.0001 Tc
(a 125 mg/d)Tj
-33.06209 -1.64706 TD
(Rozen et al.,1996 (8))Tj
10.08289 0.00001 TD
0 Tc
(1)Tj
4.78383 0.00001 TD
-0.0002 Tc
(35)Tj
5.23759 0.00001 TD
0 Tc
(F)Tj
4.73009 0.00001 TD
-0.0001 Tc
(Trasplante)Tj
7.67176 0.00001 TD
-0.0002 Tc
(n.d.)Tj
7.12 0.00001 TD
0 Tc
[(Dentro del \207mbito)-1712(Mantuvo dosis de ciclosporina, siendo no efectivo )]TJ
-14.23586 -1.17651 TD
-0.0001 Tc
(hep\207tico)Tj
14.79178 0.00001 TD
(terap\216utico)Tj
10.04282 0.00001 TD
-0.009 Tw
(el tratamiento con AINE, propranolol, verapami)Tj
20.06324 0.00001 TD
0 Tc
(-)Tj
-20.06324 -1.17649 TD
-0.0001 Tc
0.0335 Tw
(lo y amitriptilina. S\222 mejor\227 con sumatriptan. Se)Tj
ET
42.52 144.176 m
552.756 144.176 l
S
BT
/F18 1 Tf
7.225 0 0 8.5 405.3947 148.6779 Tm
0 Tw
(sustituy\227 la ciclosporina por tacrolimus)Tj
-50.22492 -1.64706 TD
0 Tc
[(Maghrabi y Bohlega )-1249(1)-4228(25)-4125(F)-4287(Trasplante renal)-895(n.d.)-5452(Dentro del \207mbito)-1712(Se retir\227 la ciclosporina por tacrolimus)]TJ
0.5559 -1.17646 TD
-0.0001 Tc
(1998 (13))Tj
39.62619 0.00001 TD
(terap\216utico)Tj
-30.0992 -1.17648 TD
0 Tc
(2)Tj
4.78383 0.00001 TD
-0.0002 Tc
(26)Tj
5.23759 0.00001 TD
0 Tc
[(F)-4286(Trasplante renal)-895(n.d.)-5453(Dentro del \207mbito)-1712(Mantuvo dosis de ciclosporina, siendo no efectivo)]TJ
20.07777 -1.17649 TD
0.462 Tw
[(terap\216utico)-5211(el tratamiento con antidepresivos tric\222clicos,)]TJ
10.04282 -1.17647 TD
-0.0001 Tc
0 Tw
(ergotamina y sumatriptan)Tj
-40.14202 -1.17647 TD
0 Tc
[(3)-4228(30)-4126(F)-4286(Trasplante renal)-895(n.d.)-5453(Dentro del \207mbito )-1434(n. d.)]TJ
ET
42.52 70.176 m
552.756 70.176 l
S
BT
/F18 1 Tf
7.225 0 0 8.5 332.8353 74.6779 Tm
-0.0001 Tc
(terap\216utico)Tj
7 0 0 7 42.5197 62.6779 Tm
(n. d.: no descrito.)Tj
ET
Q
endstream
endobj
6 0 obj
<<
/Length 5029
>>
stream
/GS0 gs
q
0 0.701 595 793 re
W n
1 g
0 793.701 0 0 re
f
Q
/GS0 gs
/GS2 gs
0 0 0 0 k
42.52 51.024 510.236 657.638 re
f
q
BT
/F0 1 Tf
7 0 0 7 42.5197 744.001 Tm
0 Tr
0 0 0 1 k
(Vol. 28. N.)Tj
4.47167 0.00001 TD
[<A1>-250(6, 2004)-4754(CEFALEA ASOCIADA A CICLOSPORINA EN UN PACIENTE CON GLOMERULONEFRITIS MEMBRANOSA)]TJ
8 0 0 8 540.7559 744.001 Tm
(457)Tj
ET
0 0 0 0 k
42.744 18.126 25.512 15.007 re
f
BT
/F0 1 Tf
8 0 0 8 42.7441 19.8606 Tm
0 0 0 1 k
(85)Tj
ET
0 J 0 j 0.4 i 10 M []0 d 0.5 w 
0 0 0 1 K
42.52 694.796 m
552.756 694.796 l
S
BT
/F2 1 Tf
10.5 0 0 10.5 42.5197 700.7149 Tm
-0.0002 Tc
(Bibliograf\222a)Tj
ET
0 0 0 0 k
42.52 462.606 510.236 218.749 re
f
BT
/F0 1 Tf
8 0 0 8 46.5197 675.8838 Tm
0 0 0 1 k
0 Tc
0.085 Tw
[(1.)-1000(Horton S, Resman-Targoff BH, Thompson DF. Use of cyclosporine)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0 Tw
(in rheumatoid arthritis. Ann Pharmacother 1993; 27: 44-6. )Tj
-1.75 -1.12125 TD
0 Tc
-0.015 Tw
[(2.)-1000(Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin:)]TJ
1.75 -1.12125 TD
-0.0001 Tc
-0.0111 Tw
(an updated review of the pharmacokinetic properties, clinical efficacy)Tj
0.2486 Tw
(and tolerability of a microemulsion-based formulation (neoral) in)'
0 Tw
(organ transplantation. Drugs 2001; 61: 1957-2016. )'
-1.75 -1.12125 TD
0 Tc
0.033 Tw
[(3.)-1000(Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0 Tw
(Clin Pharmacol Ther 1996; 34: 515-9. )Tj
-1.75 -1.12125 TD
0 Tc
0.093 Tw
[(4.)-1000(Philip AT, Gerson B. Toxicology and adverse effects of drugs used)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0.0016 Tw
(for immunosuppression in organ transplantation. Clin Lab Med 1998;)Tj
0 Tc
0 Tw
(18: 755-65. )'
-1.75 -1.12125 TD
0.134 Tw
[(5.)-1000(Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver trans-)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0.2529 Tw
(plant recipients with cyclosporine immunosuppression. Neurology)Tj
0 Tc
0 Tw
(1995; 45: 1962-4. )'
-1.75 -1.12125 TD
0.023 Tw
[(6.)-1000(Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxi-)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0 Tw
(city: a review. J Neurol 1999; 246: 339-46. )Tj
-1.75 -1.12124 TD
0 Tc
0.131 Tw
[(7.)-1000(Reece DE, Frei-Lahr DA, Shepherd JD, Dorovini-Zis K, Gascoyne)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0.1346 Tw
(RD, Graeb DA, et al. Neurologic complications in allogeneic bone)Tj
0.3733 Tw
(marrow transplant patients receiving cyclosporin. Bone Marrow)'
0 Tw
(Transplant 1991; 8: 393-401. )'
-1.75 -1.12125 TD
0 Tc
0.031 Tw
[(8.)-1000(Rozen TD, Wijdicks EF, Hay JE. Treatment-refractory cyclosporine-)]TJ
1.75 -1.12125 TD
-0.0001 Tc
0.1891 Tw
(associated headache: relief with conversion to FK-506. Neurology)Tj
0 Tc
0 Tw
(1996; 47: 1347. )'
-1.75 -1.12125 TD
(9.)Tj
1.75 0 TD
-0.0001 Tc
0.0795 Tw
(de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA. Central)Tj
33.66142 25.78874 TD
0 Tc
-0.007 Tw
(nervous system toxicity after liver transplantation. The role of cyclos-)Tj
0 -1.12125 TD
-0.0001 Tc
0 Tw
(porine and cholesterol. N Engl J Med 1987; 317: 861-6. )Tj
-2.25 -1.12125 TD
0 Tc
0.024 Tw
[(10.)-1000(Gryn J, Goldberg J, Viner E. Propranolol for the treatment of cyclos-)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0 Tw
(porine-induced headaches. Bone Marrow Transplant 1992; 9: 211-2. )Tj
-2.25 -1.12125 TD
0 Tc
0.051 Tw
[(11.)-1000(Fradin MS, Ellis CN, Voorhees JJ. Management of patients and side)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0.1899 Tw
(effects during cyclosporine therapy for cutaneous disorders. J Am)Tj
0 Tw
(Acad Dermatol 1990; 23: 1265-73.)'
-2.25 -1.12125 TD
0 Tc
0.024 Tw
[(12.)-1000(Steiger MJ, Farrah T, Rolles K, Harvey P, Burroughs AK. Cyclospo-)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0.1897 Tw
(rin associated headache. J Neurol Neurosurg Psychiatry 1994; 57:)Tj
0 Tc
0 Tw
(1258-9. )'
-2.25 -1.12125 TD
0.058 Tw
[(13.)-1000(Maghrabi K, Bohlega S. Cyclosporine-induced migraine with severe)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0.159 Tw
(vomiting causing loss of renal graft. Clin Neurol Neurosurg 1998;)Tj
0 Tc
0 Tw
(100: 224-7. )'
-2.25 -1.12125 TD
0.069 Tw
[(14.)-1000(Toung TJ, Bunke FJ, Grayson RF, Kontos GJ, Fraser CD Jr, Baum-)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0.0121 Tw
(gartner WA, et al. Effects of cyclosporine on cerebral blood flow and)Tj
0 Tw
(metabolism in dogs. Transplantation 1992; 53: 1082-8. )'
-2.25 -1.12124 TD
0 Tc
0.032 Tw
[(15.)-1000(Morris R. Modes of action of FK506, cyclosporin A, and rapamycin.)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0 Tw
(Transplant Proc 1994; 26: 3272-5. )Tj
-2.25 -1.12125 TD
0 Tc
-0.004 Tw
[(16.)-1000(Christiansen I, Iversen HK, Olesen J. Headache characteristics during)]TJ
2.25 -1.12125 TD
0.042 Tw
(the development of tolerance to nitrates: pathophysiological implica-)Tj
-0.0001 Tc
0 Tw
(tions. Cephalalgia 2000; 20: 437-44.)'
-2.25 -1.12125 TD
0 Tc
0.059 Tw
[(17.)-1000(Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et)]TJ
2.25 -1.12125 TD
-0.0001 Tc
0.0156 Tw
(al. A method for estimating the probability of adverse drug reactions.)Tj
0 Tw
(Clin Pharmacol Ther 1981; 30: 239-45.)'
ET
Q
endstream
endobj
7 0 obj
<<
/Nums[0<</S/D>>]
>>
endobj
8 0 obj
<<
/Differences[32/space 37/percent 40/parenleft/parenright 43/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 64/at/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W 90/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 135/aacute 142/eacute 146/iacute 150/ntilde/oacute 154/odieresis 156/uacute 161/degree 213/quoteright 231/Aacute 234/Iacute 238/Oacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
9 0 obj
<<
/Length1 9367
/Length 9367
/Subtype/Type1C
>>
stream
  LWLOVH+Times-Roman   @ø øøøøû<ûnú|ú
 ‹‹
 ‹‹   û   ÷  ¤¬  $v }ˆ002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  S    - B  D J M P T Q S O F V Ï U E  N È C I H & Ø G  K  R W Z *   5 ) [ Y Ó 4 Ú  	 
 × + # 0 3 « " $ / ¶ 2 6 ; ' . » 7 ( %     ! 1      Ş  L  ¡ 8 , X U   ˆ ë1¿Àh åtoäB¬5ù2äÿ	m
7
´&ƒš?¬…¼+wâ!ª@~¿~Æe¼2Å&ïV×=|êTÜ8¯½7p,¢c~«¯Ú_ . i!!Œ"$û*~§ù§ÃÖFÕ÷oĞT×ÔøQ÷0Øi»ûæØîÁ®µÎŞCÅ#!;H0J¢iñ4äû<ulG&ØI÷	÷
ØÍòØ1øPuiCVT¯E¿ÔÄ¸³ÊÏ¶_Gä™ü-G__IAUÇİÎ±É¾ªt”„‹èE£rNû*~¥ù¥£ë÷˜ëøp÷ß÷c÷EÆ¤nd˜[[d~rnFPbûûû³ûÑOr¨²~»»²˜¤¨ÑÇ³÷÷+ûh`!44`õ÷h÷i¶õââ¶!ûid‹²dùîğ°øè÷Bsû
SizûI0°ønÓ˜˜ÕŸû§wÕ‡˜~CüQpC~~A‡wø­ûb–vŒÄø¤°ã÷6İxøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½¸T‘x·ª§›­§û0ßsˆ€ƒx{yb{sfo­¹Èºµ÷±ûbÓø¨¤×ø0÷(}“`HapQ‹1Kİ÷ğÄÔØ²–‚c—‘w•kš|£‹¦¥ÁEº<û+!û!ûÚ/÷ßÆº÷Àü vø^w÷$ğ×ğ8ßğ÷Eù§t¢opttop¡t§§¢¢¦Öı›èK–Ó÷÷†WwZyVy|©Œ‹“¦”{_û{CGˆ{ü vìß÷”›MŒ~—Ãøç‡Hwv…Ey{Œ™’‹—°“€YüpV{}N‡{û*‚¦ø4§¨ä÷šäøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûû™‚¡vøZw’¢¾È÷:Ñœ÷ğ÷»t«M° Ënœ|¤‹©¯­¨¶Å®d6œ›¬‡÷ƒ†‡‰…†„Œ…œ™cs:QXDOªeáZÅj­xq‹n_koYEi¯òs{\û/˜”’”“•Šˆ–œ´¤‡¥ÙÊÄÓû*ûVv÷a«øÇŒwÕß÷vàìøi÷ˆ÷Fä*R_sVa‰ÔÜ…TvŠŠ4m{Œ—‹—«‘[ügU„„M„{÷…›AŒ}—É÷0m«©²÷æ÷÷$6fûYAArm—s}—‚—•÷Šì¯“»ªºÕ¼>ûûÑ vø`w wÖßĞ÷âø+¬wŸhblsH]‰ä°†Jqw„Mu{š“Œ•¤•{_ûY‚ƒN{÷ƒ›KvÄ÷sœ˜¤™˜™“”’“‡ƒ”x “‡›¡›¥û* vø)ÂŒwÚÜ:ß÷EßÔøx›]}›¼÷yè^ÄB[p|IDÛ¬„Yxˆ@ty™‘Œ“¦“{[û‹S}z\‰{÷gšY{˜­÷­Ì»Ã›”¬»£kJûeN}xZˆ{ûbĞ÷o«÷¯¤ĞFÒ÷cñôø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½ìû÷-ûcÙš®¯ÇÆ¥m7—û*Äø(wÑß÷Fß=Ùèør¯™YŠ–º÷ìû2{ğË‡•‚Yûrˆ€ƒuy^wlcj®µ÷Ûû%{»ˆ˜~[û;ºY×¯±›¦¦è·¶9ˆÙ§”¾™ûbĞ÷o«÷¯¤ĞFÒÀ÷rGñÃ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œüıòø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½êû÷-ûcÙš®¯ÇÆ¥m7—ü¿ø«Ğß÷ªÍ~–vrzt‹g|¦Ê÷³ğ«&÷–‰…U<midp„†‰ˆ‹…‹‡Œ‰‹¿ûÂ5©bÉ¸²¤¾¬û*¿ø§¦á÷wßøµ›ƒ‚Š‹‡f‚—¸øË†Ux|‡=v{Œ˜‘‹¯“‚aû0¬cr•bû.ûûû×2÷Àµ ¶ªNˆÙ§oë­û+Èm^l_9SŞ÷÷¾×ÔÂ»\Uû* v÷iáøš=Œy–ºøí‚ûG0~¥•œ’œ”‹¢•}jüm\y€=Š|÷ vø-¿Œwáß÷Lß÷KŞÜù™›RŒ•»÷c÷dÆ=SXpSUÅxk¤Sbv‚XF†‡ƒ†ƒÖ¼ƒZyŒ‹1py›Œ–¤•x^û’V}}S‰{÷r›Yy™°÷¯••—•Ü£¨«—ª»¡iCûmU~Sˆ{÷s›SŒ|œÈ÷¸«ªœºÁn9ûgS„ƒP„{ûb–vŒÄø¤°ã¤÷r6İÄ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œüıtøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½´T‘x·ª§›­§û0ßsˆ€ƒt{yb{sfo­¹Èºµ÷±û*«øËÏß÷wäøh÷‡÷?è$SWlXp‰÷Á†a{U{[~{Œ•’‹®”cüœmãiÚ÷ò÷÷!2bû	]L5[\££÷¶µ¬Ä×¿;ûû* vø+ÁÓß÷Nßøz›X‚—Ğ÷[öaÀ9R_rQ`‰÷Â…\{˜ kzŒ“‘‹°“‚aükF‚U†{÷k›T~œÎ÷…¹µ«±º¦eFûZG€}R‡{û*ûnÄ÷&Ö@Ôæ¤÷k²§§ĞnŞ÷EÙ¥¨İÀøiø²?u~“w]tm*AE-L¤hĞgCKyvtuš|²{¾ÀFZnfgTØ`ï÷÷ÙæÊ]´@ûTs•‹”˜™˜—˜™“”œ†¨çÏÍä¨‡|°PûSnf_İÀMaÌíÈ¦®»Ä¸B.óûŞR?bûŞÀ3M©µ£•œ²¹¬„›‰¤ˆ»‰À‰ğˆ¡€‹id‹±e÷Èµb´÷“²xîğ÷œ¢¬¢«€øè÷>oû ^]sû7#²÷Œ÷.‰ßŠ–‚š6¢÷|t6|8û.÷q¨§÷÷~0¤‡÷#ü¥W€wÕ‡˜~CüQC~~A‡wø¯û*‚¦ø4§¨äÆ÷rxäß÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œü#ıèøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûûÑ vø7«÷_¨òß7Şğøù«\§UûQAû2Š:kÜûÏB€B‡{÷˜›:–Ö÷Ï÷«èû÷Æ§² ”…oŸk¡”„œ¢¢ûÑ v÷UË²÷Š÷±÷UËûŠKüûXvù7w÷$ğçğ8ßğ÷Uù§t¢pottop¢t§¦¢¢¦èŒıø^†XwXyWy|©Œ‹“¦”{_ü!€jg}‚—€³i†wwwywk²tÂ÷ÆÖ÷"›v£vÃ÷  ÷X–¿h²\jrskl¢w¯`™‹”•‡Š‰iogVg•xÎ­¸ÈÄû*ûVv÷aÉø§£à÷|ßø|ûk›]zš´øê†NgUª|_‹û,ûû&ûÍ4ìÀÀ¤»¹ŠûNT|~A„{ä÷ëk„~t~sr…s>W×÷÷	ÁÙÜÍªkFû*’vøewø\øoøG›û{«Šš€v|‚oy]=û[%÷”†˜‡œ‹’œ˜”¬›ûW{ŸŠ•†—¤s÷û¿£N‚˜e”‹’‹’·÷÷Ô¦Î’”©û*ûmğøËw™ø`ønøI™û}¯ˆ—„z„”qB<ûqû÷‚‹’‹–œ’’½‘™ûa}¨†—„”w÷ûŠ¦P®J|tpG{rt|z||wuloxzpkªr´Òµ¼÷*Ä÷/ø-–©™˜¡ûÑ‹ù÷ñ÷ÌŸ8~—ÖøOÖ˜—ŞŸûºwŞˆ˜@üO@~8ˆwû*‹×ø¤Ô÷åáøn÷~md†pP‹û„÷=÷Dâæ³Ú‹Úí:Ù&ûHKûlŸ†¯ê²¯Ó‹İÄP6?\*95ûFûP~ø€÷Ñ÷÷I·ªr¤mlrrlm¤rª©¤¤©d‹øí¶Ÿ¡÷gñ÷|vøãø„÷>üÄ„û>¤÷¡ ›÷Áü’@~8ˆw÷ºŸ8~—Öø’Á÷ {û¡Ó‹÷¼·÷±õñ÷ÃñùPŸA~˜ÓøQÓ˜˜ÕŸû¨wÕ‡˜~CûWûÃ÷WÓ˜˜ÕŸû¨wÕ‡˜~CüQC~~A‡w÷¨ŸA~˜Ó÷b÷ÃûbC~~A‡wûb‹©ø©¦øø6÷yv*|~/‹û÷¢ø*šûïˆûœÕ•™šÈ÷ûü*|øû* vøWwœøbøs›hy˜n·û÷Xß÷¦§›­Œšû3}¬‡’‡}~uU?~Ÿ…s³xª„š‹“‹›•‘«™ûb}µŠ‡°Sêû%ûû9pd}lŠ{÷%›n€—“—™¡Û÷Üû›s‹Š‹€{€„r‡{ü vøbwÌ÷rûUßo ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œû³ıĞ÷›K–Ó÷÷†XyWxXx|©Œ‹“¦”{_û{CGˆ{-~¯øø´Ñá÷~ïø~÷<Û\ÄûÕQ­"¼ÜÀµ²ÆåĞLû ¦¤u÷hvs…‚z„|}ŸOw‘q"?D)9­a÷C÷>¬hNGZ\C0MÀ÷Wu©ûh  –—¯«jç÷
ãØóû*‚¦ø4§Éï¨äzïîïwäŞ,÷ÑøÒ§u¡oouuoo¡u§§¡¡§û[§u¡oouuoo¡u§§¡¡§û]üÒÒøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûûÑÚ÷ ÷oøŞ¿h²\jrskk¢w¯”–‹“”Œ‘†Š‰hohVg•wÎ­¸ÈÅûÑû1vùêw»à÷Äû6ûáZ÷÷l÷[¶ñ÷î‚›û@û@û‹ûLûµ#ë%²a§t²tûÑû1vùêw÷\à÷±÷Š÷aó+ñdµo¢d¢{÷5¼ûûlû[`%û(”{÷@÷Ö÷‹÷Lû* vø)ÂŒwÚÜ:ß<÷İBßŞ÷Şùmf{~r~t‘“{t—v–s‘u‹UhiI}¨ª“š§•˜ˆ„™¡€¯y¢…¢‹Á©©Ö ü1ıÒøx›]}›¼÷yè^ÄB[p|IDÛª„Yxˆ@ty™‘Œ“¦“{[û‹S}z\‰{÷gšY{˜­÷­Ê»Ã›”¬»£kJûeN}xZˆ{û™’vù&÷CñøùŸû´wÚ‰™}Cüd\€wq|†‘£„²|›qqutp_²nÆ÷ ÈÓ÷øÓ™™Úœ‹°f÷È³c²÷—±x÷ñ÷†ğ;÷¦€øå÷DÅo½\§ršy’Z™g è¡²¶Ú÷.Çû<û¬wŞˆ˜AüQA~8ˆw÷â¦€÷%ìÒô§ û÷Ì<Yb)Š› -Š÷y§Ã÷È]0¦€ ûÈ*O]ûO|“¬÷÷VŒĞdûÓ}¯øş¯­÷ø?÷ùC÷Ş÷_û÷#ûSûTûû#û_û]÷û#÷T÷S÷÷#÷]ûŒûT:û	ûû:÷	÷T÷Rİ÷÷÷ŞûûRœ‹÷Á¤÷®¯xññ÷}÷Üù'Ÿdv—p¬ûb÷‘÷¢ÄÀè÷/Êû7û§wÔ†—~DüD4…„=ƒw÷¨Ÿ=’—Ò÷XÃ÷‚ûÉNø"Kcû=Š÷Šì¨—’½÷Å]1Ó‹÷[´ø4wšùGü5÷r÷X÷i÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œü“ığğùVŸ^}˜lÓûøÌwûdüOû!}xY‡w÷ZŸ\Šu™ª••‘›¹÷
÷š´*•t”l‹pzƒWw†÷—û{÷÷§Ó‹÷[´ø4wšùGùVŸ^}˜lÓûøÌwûdüOû!}xY‡w÷ZŸ\Šu™ª••‘›¹÷
÷š´*•t”l‹pzƒWw†÷—û{÷÷§œ}·øOv÷M²§÷ù÷yœ=AOp5‹û+,÷÷K÷Så÷	÷(öÒNû°¡‚÷tvƒu|wŒŒ{x’b™Y“a‹ûZ‹û!û#‹û]‹ûf÷û÷_‹÷‹÷ ¿¾×Ó•v–ù÷ ¸ø1·xùTùŸû~wå„‘k4ûã‰üøuû?w¶Œ–„µ[üM%~y8ƒw÷Ÿ>z£ğø¸øJü¹œø¤ïšŸÚ‘ûÑ‹ùé÷rû^ñŒ÷i ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œûĞığĞ÷ÌŸ8~—ÖøOÖ˜—ŞŸûºwŞˆ˜@üO@~8ˆwÓûF÷Gwù¯­÷ø?÷ùPûEûŒ=¶5÷ ÷2¥ò÷‹÷E‹÷_û÷#ûS‹ûT‹ûû#‹û_‹ûÁûâS®u©}¥…¹T=Í÷_÷,’Œ‹Œ²ûøûT:û	ûû:÷	÷T÷Rİ÷÷÷ŞûûRÓ}·øúòò÷ü¶ùSùŸû{wÖ‰r(û¢=`slakTtJO\®nn®‚°Û÷ÔÔ––ÚŸû®yÚƒ•BûËû@İ6÷:÷HÙİ÷P÷™ğ› Ùd‹±øß±”øŞøç÷Dtûhjq%û–øCøöšü¡xû>¤òŸ°¨÷÷qüHüö|øÆ-‹÷Èµb´÷“²xîğ÷”¢´¢Ïøµøœˆ÷#ü¦wÕ‡˜~CüQC~~A‡w÷«Ÿ@{šÒ÷p÷&‰ßŠ–š7¢÷|t6|8û&÷q·¨§÷÷~0÷ƒ‹ùö·øœğùïŸFyĞøQÓ™™ÔŸû[ûoüû{øûZwİ†˜~Dü+&|x;„w÷}Ÿ@x¥íø$÷ü·™÷øÎüV9€~<†wÓ}¯øş¯­÷÷"÷rÊ÷÷X÷i÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œü“ığèùC÷Ş÷_û÷#ûSûTûû#û_û]÷û#÷T÷S÷÷#÷]ûŒûT:û	ûû:÷	÷T÷Rİ÷÷÷ŞûûRÓ•vù#›ù;àùKùŸû`àxÆ†™‚m}„qmû&üû,÷æmÍ©‹™¤–Êûàw½ˆœ{±6÷‹üºš÷pøÆ¨Õ››ºÓ}³÷É÷®³«÷øëùW÷ãû’xÙ‡•@û4iOq?û3'÷
÷O÷Kì÷÷%ôĞUûµ£ƒ÷fuu„{€s…€€¡Ej‘\û[û"û&ûbû|÷A!÷K÷÷Â÷\Å™šÃÓ‹x°øá°xòñø÷œù?÷â÷bû)÷ûû wÕ‡˜~CüQC~~A‡w÷¯÷‚÷&÷÷clû…ûU#)ûa\~”«ø­”‘Á÷Q÷	ûûLû*~°øâàÙ÷ùÑøJù?‚‘yuƒ‡w‹ûeûû€Š‰Šˆ‹‰‡‰‘Š÷ƒ÷5Yû.&O?;u„«^¡l}pr}~tb·uİ÷5÷ ò÷.÷@ûÄû)¦µà÷XœŒ’û* v÷;ËøQw÷·Ú>Øèøk÷;Ë&øQ_ûÎüQK÷­û;Ø÷;ğ<Ëû„÷‚÷éû*}¯øçÆ÷ÑÚgÒĞøC÷lêk¹+·àÏ¹¤°ÅÚKÂ/,MXûdš‡³Ö¸«Ê‹Ì¸^L^r_cnpwvWyÁ¦†zªĞ»p¨XO8QICqv“ h£c‚ys}~ug·vÖ÷1÷ë÷ü€÷÷÷Ü÷÷Tø)©r¤mlrrml¤rª©¤¤ªûıªr¤mlrrlm¤rª©¤¤©÷£~²÷
­i·÷©·÷ª÷ß÷Óø³ßù¼ø÷<û!÷ûNû_û6û0ûVûS÷7û)÷cÑ¶–¸ï©<h\M‹ûDû÷÷C÷O÷÷÷:÷,÷ûû$#M,GqšªŒ’ŒÌ÷’G€ew´{–h‹&,ûûG±[Á³¸§¶¬[š¨t¼ëá÷÷û€¡[tBmY¿pzqytgs¬¾êĞíÎ¦›ud-‹÷¡³÷½±xîò$ñ÷{÷Úø±øw÷$Ñû3ûšwÕƒ“‚DüFCŠp9‰w÷¬Ÿ<Œ|šÕ÷HŠ¤¢ŠÚÅ–¡²È­®ÇÏû‰!S\ûæz‹t÷™§’‘­÷ÍY-û*}§øº÷‚š­ç÷‘äøh÷m÷Bßû[w„eLª÷1îê÷;«‡šûv‡ûMû;ûûDäû÷÷áê÷2jû cME4Sé÷'²­”™¡˜·´å¾Cûü›v£v÷ó÷Û÷ û÷h÷Tø)©r¤lmrrml¤r©ª¤¤ª°§ü¿h²\jrskl¢w¯p•”‹”•‡Š‰iogVg•xÎ­¸ÈÄü’vùFw‚÷º÷±ù8IûxıFÎû*™vøèÔŸø@øTùšü|_`%œƒ²Ì¢›Á‹÷mûZüèÌû*‰w÷—¶ø§©ç÷€ï+ëôø^ø!÷5/÷
ûû4'û û
Ô:öÀ»±¹øŒˆmû%ûû>qw÷…›÷3÷<‹÷ô+bv‡‚uod}j>\Õ÷÷±ÊÏä¸4û;û*Äø(wÑß¡÷rIß=ÙŞ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œü"ıäør¯™YŠ–º÷ìû2{èË‡•‚Yûrˆ€ƒuy^wlcj®µ÷Ûû%{»ˆ˜~[û;ºY×¯±›¦¦ä·¶9ˆÙ§”¾™5 v÷pÎHÍ÷ÍĞø©÷pÎûn÷pI°ûqûoI÷oûpÍ÷pû* vİßø›`i¡d¼û.÷V¨¦ïè½®Ì‰™û_}“Š‹¢Š”‡Œ~Œƒƒ{|ûû‰ø3†Oxz†>w{Œ˜•‹’¯”ZüuU‰‰B€{÷~›M~”´÷I÷ûLr‡‹…ƒ‚…y{÷K“v˜ª÷—®š«÷g¤ÏwÈ×÷r¤ÌÖ÷q¥Àù—÷šÑf³Hûû ûû;»WÕóë÷÷ûø2eYYbyDd{’ oŸr{‘oû û	ûB¾QÍõï÷÷™‰–‡ƒ£—‰£·§’ °‰¿ÀûğıºÀø…÷£û:û<du¥·ÏË÷?â²ªf^ü÷¼û:û<cu£¸È°æ¹½£¡¡˜œ‘Š„’•š„¨ƒ‘w‹}û vø­÷n­Ä­÷n­÷ëø©ÚKË<<KK<<ËKÚÚËËÚiOZZOOZ¼ÇÇ¼¼ÇÇ¼ZO÷º–vù"ú1ú6ùŸûZwÂ†™‚l|„k‚sûûèû÷épĞ‹Š‹—¤¡•ÂŸûŸwÊ‡‡­:­9 û¯û%øƒ ˆ•‹˜¡—‘ÀŸûˆwÉ‚‡ÒûSÌûC†èû¡š÷.ø;‘y‘|‚‘|¡Uª;±*œ[ª4™Ù÷ƒ–ªÌ÷H¦Ôš³–©šµ›—»‘Ó‹ù÷ñàùeŸXz–ë2û|÷÷Q÷QÇÇ£—ÎŸû˜wÇ‡’ˆtrxs4:tuº¶û@û0÷WàŞ–—Ù‘û¬xÙ…–8ü;8€=…x÷¬=‘€—Ş÷D¥¡õ!Ø>ÀF‹tày‚ˆO‰wÓ’v¡vødw ù4pùIøG›û{ªˆ˜y~‡u~l0ûr<÷ktÉ„‹˜£™“¶›û^{µŠ™v­%/û\kâH÷C‹†›Š“’Ÿ˜”¬›ûG{¢Š”€ŸX÷ûék˜‘’‘‘”©™÷÷ƒåû°^œ‹Œ’“ŒŒ»÷÷îœµ’u¡øW–÷\š’‹÷š”ü}¦
ß
_÷ùendstream
endobj
10 0 obj
<<
/XHeight 677
/Ascent 684
/FontFile3 9 0 R
/StemV 84
/StemH 0
/ItalicAngle 0
/CapHeight 662
/FontName/LWLOVH+Times-Roman
/Type/FontDescriptor
/Descent -215
/Flags 34
/FontBBox[-168 -218 1000 899]
>>
endobj
11 0 obj
<<
/Name/F0
/FontDescriptor 10 0 R
/Type/Font
/BaseFont/LWLOVH+Times-Roman
/Widths[250 0 0 0 0 833 0 0 333 333 0 564 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 0 0 0 0 921 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 0 0 611 0 0 0 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 0 0 0 0 444 0 0 0 0 0 0 444 0 0 0 278 0 0 0 500 500 0 0 500 0 500 0 0 0 0 400 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 333 0 0 0 722]
/LastChar 238
/FirstChar 32
/Subtype/Type1
/Encoding 8 0 R
>>
endobj
12 0 obj
<<
/Differences[32/space 58/colon 75/K 80/P 82/R/S 97/a/b/c/d/e 108/l/m/n/o 114/r/s 117/u/v/w 121/y]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
13 0 obj
<<
/Length1 2977
/Length 2977
/Subtype/Type1C
>>
stream
  YFBNOF+Souvenir-DemiItalic   Jø øøøø)Áûûªúo
 ‹‹
 ‹‹   ı   ù  (š  ’ Nfr}ITC Souvenir is a registered trademark of International Typeface Corporation.ITC Souvenir Demi ItalicITC SouvenirDemi Italic    3 F T V N O 1 B M C S  D W  4 Z , X P E    ²$—6”( ÕR®¯v·Pİ¯	V	©
:ûÊ÷‹³ùËÃ÷¶÷¬÷Y÷ä÷È÷œ¥VÃ*‹CUSŸ‹by—„šˆ÷l¢¯«™„’€‘oœˆ„ªvæ}»[Ş ì¨ğØ÷÷/û:‚ûûÎqdˆi–ƒ”…›”‡v=ükNƒ\iƒ‚ƒ}o§‹Ÿ÷M£¬Œ«™‘‚’|–‘ÓøEàšˆÁ÷ ËÏv?PhVXpSlC~L„E|Ü÷÷ÏÕ÷?÷j÷'÷‰÷Jï˜÷™­÷#±p©l¡fX”a48nQINW\=9û÷I÷ÍÔ ¬ÃŸ—Â¯¨š}–|}w}ƒ€o]aqS@_´Ö‰ŒÏÌ•ÓõÓ©¨yj9û)iK‡û|ÎøÌ÷÷8Ñ÷A÷¦|ÇÅ™¬½·§­ºÁ÷'û‡pà³³­ëX-‹İ¨¥Ÿª®o¤p›£cZ“\SS~l\cqm\[û&÷~¤8ZZxacq•³¬¨bjpqi`³l®{v¶¾ƒ»©|îø³÷/÷C÷÷V†n„nm?Ğ^ÑèÏÔÚ°Šz†J‹s]¬‹˜”–¿ŸŸ“ÀŸš—’‘‘’•¬JwÀ¢”¸¦­÷J•‘¥‹” q†~F}v€„Vˆ{<Zûy(‹n‹xŸ‹©‹’©›â’²Ó®¢„«oh@k}iy„m~sm¿[}‡tˆ}÷Ş|³øê÷.÷+÷7÷,÷5÷5ú7÷°‘­¢¨ÖK·E/H:>hœ›œĞP²J)J4<dª‘««¢‰»jnKn}r{‚k|ul½ŸYi~I„hiûI‹~’…”‡÷”Œ‘Œ•‘˜¦˜Ì–È™É¦Ã›®­Ì¸‹«‹–o‹n‹h|A„fpû‰ƒ‡wƒ}’…•‡÷•“‘•¢¿÷k¹›µçÅ§—psub‡pƒaiû+ku—v£ªÕ¥–¨“½š¦¬Lvº©|³øé÷(÷4÷?÷8øM÷‡w‚aws“r§®Ê ˜«“¾œ¥®Mr¼´÷{‹İEºC‹)KC<_’¦‘§¨¤…µjqCjr{„h~ueÀ¨Osƒ]†sbûaˆ}Šw‹÷Ÿ¡¤œä™Ó¸÷Oê‹­špkw…k‡vÑ‹³ùÌÅ÷¸÷•÷W÷ß÷¯íî™²äìµãÛ÷ĞYÀM¡VC‹Sû´sl†m~•„”„œ”‡u>üj‡t†ayz„„}‚ƒ…€ƒ‚„‹|‹p«ŠŸ‹÷U ¥”¤™‚’€’{–‚“Ôøu£‘¢’•›£¬¥‹×‹Èl‹9‹KYQVjZnRR‡|à÷ğÒÕ÷7÷b÷ø:®q˜s§§Ë©˜¦œ’¬–£±MlÃÇ±÷P›Ê¨’x›|k[eusµq\[û5ûû,û3#Ç2÷ßÊÄÔ°û^X~Å´Æ¡Ï¨½©±µ²¶œhdSx?sXgyhT]û¶|³ùH³ô¨w’s£¬Ú©˜«Ÿ“²—¦¬PoÈôøá‹”z‹iû3_bp·“‹f|Ñ÷éè÷x³÷X÷H÷÷?é¼‰ˆ€w™~«¼± ¡b©¿y½İÛ®ÆÃ½¿±ÜÖ÷Hæû	IRjXdÆ÷Ğ‹¤|–s‹};vku„j€om³˜`÷pûtÉ™QY@Xû2-Vwµ»ºØ¡¶®²¼·ûR‹³÷İ÷÷3÷1÷wµ†±“¿•¹÷˜Ë©„[¼»Ë²²x¥b3X4Coª’«ª¤†³jûa|„h|‹uy›…™„¢Œ}tWûÄ‹q¨‹û|İ÷ñÔÖ÷?÷èÎHpÃÇÀšÊ§·®¡¬±·×R)è­¬£°ªv¤sœ¥fW–_û7û+ûû;ûñ@÷	ÈÇœ«¿¢š½±ª›~–|m\=‹,E|äø³÷-÷Dñ÷0÷"÷¡x*†wˆv‹u3ïgÕäßÅÓ¼¹Ì©æÛÃ{İFcledEÑ™‹M8Hû+gv¢°°šË’±•½’±”³‹²¨…ŸjlJpmv‚c~nl½ \€‰€ŠûŞ|÷5÷÷5Ú÷Rû%÷R ÷7|¼Ä²À¹c¢aVTdRaºt°P·÷©¼Å²À¹c¢aVTcSa¹t°©|ÚøúĞ÷÷R÷L÷R÷ó|÷3÷Oê÷F÷lü
U‹÷.§©¡œ ¦¯“¬÷c4û8Ûš™”™’”Ë¡˜‹–‚•—n—~N¦DšH‹?‹@wMaN`bL‹?‹û÷c÷iÂzÚw‹E‹gsiowktb„d‹BM¦Óv°€³\^of_JÃ`ÁsmÉËĞ1ûW÷Îîø³÷÷6÷+÷ ÷¼øS¥‚›nw4r…vz…kty™‡š…£ƒ‹€t‰/‹R‹<¡XX ·iÃ¨§¤ ¤au+-_u}¢lklwj`¶z°÷÷÷+ßÅËçÔ÷'÷¸{ÀTdmhfp—|œx™zƒuVCû@LG‡÷&¸÷‹³ù ³Â÷³÷/÷°÷÷6~E‹Xg„„ƒ‹‹q¢ˆŸ‹÷O£¬«˜’‘}–€‘ª÷PæÁ´Hİû7‹w|‚ˆ€„~‚ƒ{g¶£÷0¥®­®jyyÇyÈiÏmÃ6÷÷s÷]—”“š’Ÿ”–¤¥ruû"tq„pz•„˜ƒ’†ˆ|zz€[`û<û$Feª÷P•Å‰™¹©—”–’‹š‹¦rv‹ûLsj…m~–„”„š•…x÷R|³ø<³÷+÷Eø÷!÷÷{„hQih—o¦ux£±|ªïÌçá«‡xˆxw=ÓaÑêÊÆÙ·±Ë¨ßÖ¼€êJbsbfDÌ˜‹MKYû';iz©«¢÷O¡÷	Œ³h†y‹]iu‘b„~6€Fp<}ce1W‹l‹‚¨‹¤‹¥“³¤è‘«—Á««~klJn~myƒgrm»œ]|Ò÷şÒØ÷?÷…÷?÷ä|Ûß¦¿ÉÅ½³ÕÙ÷(ûÖû8:pTMRVd?<û#÷D÷ÒEtÇÈã²÷-÷Î¤RP4eû3û©|á÷ìÕ÷x³Õ÷?÷k÷øzø9»ndŸQû2ûû5û+"Ù4óğÑÑã¯„+‹tdª‹¤É¤” “¼œ¤´GjÉëøà‹ }”w‹gû/n]|š…–…œ‚wûZüµvtšœ€{¢‡¨¥Á¡Ğ©¸ª ¬®´Àš_^V{Fs[fxi[\|šøu“÷‡¤÷èùendstream
endobj
14 0 obj
<<
/XHeight 757
/Ascent 732
/FontFile3 13 0 R
/StemV 190
/StemH 0
/ItalicAngle -10
/CapHeight 732
/FontName/YFBNOF+Souvenir-DemiItalic
/Type/FontDescriptor
/Descent -15
/Flags 262242
/FontBBox[-123 -278 1296 987]
>>
endobj
15 0 obj
<<
/Name/F1
/FontDescriptor 14 0 R
/Type/Font
/BaseFont/YFBNOF+Souvenir-DemiItalic
/Widths[340 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 320 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 780 0 0 0 0 720 0 780 680 0 0 0 0 0 0 0 0 0 0 0 0 0 640 640 540 680 580 0 0 0 0 0 0 360 980 680 640 0 0 460 520 0 680 580 840 0 560]
/LastChar 121
/FirstChar 32
/Subtype/Type1
/Encoding 12 0 R
>>
endobj
16 0 obj
<<
/Differences[32/space 58/colon 65/A/B/C/D/E 73/I 76/L/M/N/O/P 82/R/S/T/U 97/a/b/c/d/e/f/g 105/i/j 108/l/m/n/o/p 114/r/s/t 118/v 146/iacute 151/oacute 238/Oacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
17 0 obj
<<
/Length1 5624
/Length 5624
/Subtype/Type1C
>>
stream
  YZXDAM+Souvenir-Demi   Gø øøøø)Áû?û¯aúƒ
 ‹‹
 ‹‹   æ   â  3š  é N_koITC Souvenir is a registered trademark of International Typeface Corporation.ITC Souvenir DemiITC SouvenirDemi  %  0 C K F U J W P  % T D S Q Ø O  E M B $ N * / 5 3 6 » . " & 4 1 - # H G Ó '   b İMÁ¡#s©”íx§eflñ	w
’
ø´>ö-ÿ˜Ií€ø•.¼dûÊ÷f|×øö×«÷Wø(÷Wø;|÷n÷M÷3÷t÷wûH÷,ûpûnûDû1ûr!°+×BFÔôdï×û1`÷N÷Í”Ë©ÆË¬ÁºÖ÷3·ûHûû_ûBû4m|Ğ÷û×÷x³Å÷7÷W÷A÷qù'©‘Ï\lRxmx†a…p{˜†—„œ“†vu‹l‹uûôI‘NÅak¸Î~Â÷6÷è÷@÷5ïû!V\xjbû)¨Œ©œ¤¤œ§›ªÜœûOHx 59†êÈûòûW÷ø˜³Ä÷3ä÷7÷1ø¶¸Â¦¿ÁZ¥Z[ZlVZ¾q·Güö„i~w±‹bluslSØz¶ÇÄ¨¾«©¹‹ÄÀ÷ò©‘Ï\lRxmx†a…p{˜†—„œ“†vu‹l‹u1|Û÷öÑ ÷A÷E÷0÷_÷@É•Ì‘ÇÈŸ×µ‹Õ‹ôû´2‹û0‹û%'‹û<‹û'÷2÷‹É‹¿–¿ª¦šÁµ‹¯‹š|—}‹w„}gcbsUJY·Ê}‚ÎÑ†±÷ß³Ÿpe8ûpI†û¢‹Ø÷ÙÚÚ÷7÷†ø&Å§«®²kŒmP÷µ‡‘]cƒ~f„‡r€^~v{ssˆp‡u‡y…‹q‹dª‹¨‹ŸûÙG ‚Ê÷¥´¯¶e‡mW†¤¸ûò‹³ø-³Ä÷3Ù÷7÷#ø¶¸Â¦¿ÁZ¥Z[ZlVZ¾q·Jü7~Œp†~‡„ƒ†„†…ƒ„‹~‹tƒŸ‹÷=Ÿ“¢˜ƒ’‘„ƒ‡’†˜Œ¦‹˜÷œ©‘Ï\lRxmx†a…p{˜†—„œ“†vu‹l‹uû|³ø4³ˆ÷‘÷÷A÷Ğ÷fÄE÷2Ê­´ˆ¬«a‰tûthŒk{–„–ƒš€x®û°û Õû¤fƒ·‹¢‹ ›œ ³—£²Ö«Ú¡Ü–µ”¯Š‹¢£““‘”‹˜‹«a…v‹Twhlh¹“‹]hr9|hm|Ğ÷ÿÓ¥÷@÷u÷@÷É|÷%÷!í÷1÷*ûîû!?BvXQX]iIEB«GÄ\_ÁÒyĞŒĞ+{÷ÖÕ¢ñæä¡(C=~û'|÷5÷&÷4Õ÷R÷?|¸»©¼½[«]\ZnWX¾n¹÷Ç¸»©¼½[«]\ZnWX¾n¹÷>‹ÒøâÒÖ÷J÷Ú÷WÒùpup„py–…˜ƒ–…¡€‡t‹vürvtu€€…~ƒ€…‹yp¦„¡÷×ôñ¤××ÑÒªïî÷bï1ÑÏ5+–"$û1Ê‹¢Ò÷@Şû#û2û/9ûû;?Š¦Ñû*|ÒøÏ±÷8ë÷>÷§÷Ëo’^–¯³µ›­ì‡5‹¸¨Œ¦¡¡‹«v˜¥dB—]#û]ûûH÷˜Ù‹%`X{iYv¢®k›}‚˜tsyusb¸m­|xµ¶„ºÀÄ—¦¸º©¬»ÃèE§?Ÿû|à÷îÔ¢÷A÷X÷~ŠËŒŸ÷
ŞÕ‡0Ôª¦ ¬İû"§Lû+û&û1û-÷.÷$ÅÄ «»¡›­¨«›šzz~}€€mmava‡1fàÚûf‹³ø-³å÷7÷‘÷j®µœª”›  Ÿ~¥®±ª¶kª`QZTZs¬†„Ò^uMvƒvxƒmry—ƒš„ ”†‘u‘w‹v‹™ûK}‹o†~‡‚†ƒ‡~„€„‹{‹k©‹£‹÷1£©‹«›€’~’ƒ‡”†˜‹§‹™ûL³÷ß÷ãàÚ÷7÷]÷@÷†÷©«Œ°¢¥ £–§ß¢"IaƒZrhsypzm{||}ƒ~]Ñ~­÷!ò÷÷"÷2÷û%OYr\_¥‡„¹ilûeg{–„•‡­z‡yhü}‹o†~‡‚†ƒ‡~„€„‹{‹k©‹£‹÷1£©‹«›€’~’ƒ‡”†˜‹§‹™m|Ğ÷ÿÓÁ÷N¥÷@†÷t‘÷@÷(÷ù(š–œ• ªl‰v‰^dŠ‰ƒxjW0†ƒ}€–ƒ—™›™“–û•üÉÔ÷É|÷%÷!í÷1÷*ûîû!?BvXQX]iIEB«GÄ\_ÁÒyĞŒĞ+{÷ÖÕ¢ñæä¡(C=~û'm‹³ø-³Ğ÷7÷:÷7øÅ÷·½„Ãg²±gTšXJUtZc¥‡„¹ilûeg{–„•‡­z‡yhûS~Œp†~‡„ƒ†„†…ƒ„‹~‹tƒŸ‹÷=Ÿ“¢˜ƒ’‘„ƒ‡’†˜Œ¦‹˜÷/¦‹ªš£§œ¦˜¬ÓMTû5~Œp†~‡„ƒ†„†…ƒ„‹~‹tƒŸ‹÷=Ÿ“¢˜ƒ’‘„ƒ‡’†˜Œ¦‹˜m|Û÷óÔ÷x³÷A÷[÷7øø\¡dj–^û'û ûû'ûëû÷È¿ŸÄ­^‹z¾ï£©‹«œ€’}’‚ƒ†•…˜Œ§‹™ø©‘Ï\lRxmx†a…p{˜†—„œ“†vu‹l‹uü	qŠu}tqzn{l3xñĞÒ¢÷ä¤¤€x›urpûò‹³ù9³Ô÷7Ô÷}‹o†~‡‚†ƒ‡~„€„‹{‹k©‹£‹÷1£©‹«›€’~’ƒ‡”†˜‹§‹™ø ©‘Ï\lRxmx†a…p{˜†—„œ“†vu‹l‹uE|İ÷OÊôÎ¤÷<÷5÷6ø˜÷»Ñx¾M¯§ZM”SZû2~Eh¬~¨Ê”Ë‹ÈË¨^OiûûHhû"$áWéÈÇ Ã­^‹z¾ï£©‹«œ€’}’‚ƒ†•…˜Œ§‹™û6÷	kcŒkuhpyqvjbu­±ÛÓ®Ò÷|ãøíÔ«÷Wùøºw•—l¦¤œš£¡ˆĞ…†š}•}“J·2¡=‹ûm‹ûXû>‹ût‹ûr÷Jû&÷h‹Ğ‹ÔœÆ®°¡Î¾‹»‹{›x‹r‹wq{{[]KmL@FªÍcjÃyİÌÔšÓµÈÆ´È¯Ò°³~r«¬r—rœg÷¢‹³ø-³Ï÷7÷,÷7÷,÷78ùñ÷Æ½…¾e¯ªjZš_GKtQdÁmV¦OLQq]c¥‡„¹ilûeg{–„•‡­z‡yhûS~Œp†~‡„ƒ†„†…ƒ„‹~‹tƒŸ‹÷=Ÿ“¢˜ƒ’‘„ƒ‡’†˜Œ¦‹˜÷*¨‹®£¡œ¢—¨ÍŠF[û/~Œp†~‡„ƒ†„†…ƒ„‹~‹tƒŸ‹÷=Ÿ“¢˜ƒ’‘„ƒ‡’†˜Œ¦‹˜÷*¨‹®£¡œ¢—¨ÍŠF[û/~Œp†~‡„ƒ†„†…ƒ„‹~‹tƒŸ‹÷=Ÿ“¢˜ƒ’‘„ƒ‡’†˜Œ¦‹˜‹³ù ³×÷J×÷vtu€€…~ƒ€…‹yp¦„¡÷R¡¦’¦€‘~“€‘u–¢‹ ør ‡¢¡––‘˜“–‘‹¦p’uûRup„py–…˜ƒ–…¡€‡t‹v÷‹³ù ³ğàø4àøî÷¨û÷QWÔCôOÊ¦r…ŠfûqlŠjs†…»|„fŒ`üOŠ‰ˆ‚„y|‡{…z„ƒ„‹x‹i¸¢‹â¢¸ˆ­ƒ’z’{‘|„ˆ”‰—Š—ø7÷ÍüC›s²My{š™‹¡È›Âø³Œ——”’š›‘œ’“’‹‹­^ˆt‹4t^ix“„œ„›…š‡’y‚Œ©‹³øşÕ÷Š÷J÷Š÷vtu€€…~ƒ€…‹yp¦„¡÷R¡¦’¦€‘~“€‘u–¢‹ øq¯ˆ¶÷8‹¹£™š¢–ˆ–‰•ˆ„¾|—‚’sŠ‹ü”sŒ„‚|„Xˆy‰ˆ€‹€‹t™|£‹¹‹Ş÷‹¶‹ˆy‹gå‹³÷Ø÷«Ò×÷J÷~÷W÷—÷Åî›²_ßû‹Xo`‹mi¯Œ£÷X¬¦€~“n›…š~©iãcáJÑÛ°ÓÊ‹é‹ÊfÃS§Z¤LU‹ûøŠup„py–…˜ƒ–…¡€‡t‹vüqvtu€€…~ƒ€…‹yp¦„¡÷S¡¦’¦€‘~“€‘u–¢‹ ŠøT ‹©šš›š± ÚÍg4û	û f-‰÷|Øù
³È÷J÷óà÷‡øğµ‡‘°›™•“‹œ‹©lt‹ûUup„py–…˜ƒ–…¡€‡t‹vû¶0”+ÑHRÇïxÓáò¡ÑÆÄÏîß÷»¨•£—™’—’«iŒr4riŠky—„™„£•ˆnûÊU‹Dq[WoJqUMO¤Èmr¼ŠËÁ÷f|×øö×¹÷N«÷Wá÷té÷W÷„÷(÷ù(š–œ• ªl‰v‰^dŠ‰ƒxjW0†ƒ}€–ƒ—™›™“–üıÃÔø;|÷n÷M÷3÷t÷wûH÷,ûpûnûDû1ûr!°+×BFÔôdï×û1`÷N÷Í”Ë©ÆË¬ÁºÖ÷3·ûHûû_ûBû4÷¢‹³ù ³Şàøz÷Jøc÷Âû ÷û|³†ª[‹ûWqlŠjs†…£„–~zƒ‹‚‹‡ütŠ‰ˆ‚„y|‡{…z„ƒ„‹x‹i¸¢‹â¢¸ˆ­ƒ’z’{‘|„ˆ”‰—Š—ø=÷Dü0d˜ˆ·‹¾ µ÷6ø&üFvtu€€…~ƒ€…‹yp¦„¡÷R¡¦’¦€‘~“€‘u–¢‹ øw¥š¦“‘Ÿ‘¤¢|˜xûN^‡€bzå‹³÷Zİø³‚÷,÷Ô÷­÷
¤¿†°°W‹·«§Î•®÷¬{’u¬(‹zt`‹kk±‹¢÷=£¦¨š„’’z•†ƒhóûaøtv¼—S‹fy‰jyoXsYuYXûWûeûgû„y„‡{€ƒƒ‹}‹d¸¦‹÷&÷Ó÷÷öû{•‹ÔøàÒÖ÷J÷•÷ø÷+Ïƒh‹­³†Ä¦¤‹·hi–f‹Dû+÷N˜•–š‘’·Œ ©·‰…¥§„›u˜{–}¡‹¥‹•Ÿ‹¢‹ ‡Å~›™p‰{‹ügup„py–…˜ƒ–…¡€‡t‹vürvtu€€…~ƒ€…‹yp¦„¡ø}¸“µ˜”¤˜²¦y™yqtmy{\`dˆOûŒ’ò©|ÚøùÑ¼÷H÷Œ÷D÷÷ønR™FŸÓÌÏ«Ä÷8ƒû"‹Á¤—œ£¤‹´„£‡™€“’I­:A‹E‹A}RaRadG‹D‹I­RÁf¶nÏy¾‚¯„Ç~«{«|o‹h;6gF_\—£fj¡}¤v«} |›p‹n‹wp‹o‹OĞU½sÆpÎ€Ì‹Ü‹ØÌ¼È¸°Ñ‹×‹ÅpÁ^°dªO[–©‹³÷€Ø÷ÉÑÕ÷J÷r÷W÷”÷¨åí•Ü³Û²ÏĞ‹ê‹ÕcÄK¬P©HK‹ûÉup„py–…˜ƒ–…¡€‡t‹vürvtu€€…~ƒ€…‹yp¦„¡÷O¢¸ˆ­ƒ’z’{‘|„ˆ”‰—Š—øa Š¢›ššš§ŸŞÈZ5û
û`+~Y‹Óù ³Ø÷JØ÷vtu€€…~ƒ€…‹yp¦„¡øU¸“µ˜”¤˜²¦y™yqtmy{\`dˆOfR}‹Æøk ‡¢¡––‘˜“–‘‹¦p’uûRup„py–…˜ƒ–…¡€‡t‹vå‹ÔøãÏÖ÷J÷÷Wø^ÌÊ—³À¼°¨ÂÉ÷2Î&Ï§ÔÅÜÄlºZ§¦\TWûÿup„py–…˜ƒ–…¡€‡t‹vürvtu€€…~ƒ€…‹yp¦„¡÷NøãœŠ¤—˜œ›¯Œ ÉÖ€<!ûX4y:÷*¯ÈyÁU‹H#0e1um‹šzzš¡ YûWŞ÷Ó÷ÛÊ¡÷@÷K÷@÷¿ø}GC~`TS_qFEû#÷;÷¥¥’¤¬}¬wcK:€[tA’­‘¢d{\LtR1÷V„Êì÷K¢÷ĞP®P™Í¶®ÊÚ¿x¿g²¥£Œ°Œ­µhŠkT/5ü>õÃÃ÷ÕÔœ%SM~ 8û¶‹³ø Ø÷*÷å÷7÷‘ø(«­¯†¸¶`…mn÷“Š»›“£n‹©«¢¥«½KbDLlImqT‹GŒSxz}|…„ˆ‚d¤‹«˜û¡}‹o†~‡‚†ƒ‡~„€„‹{‹k©‹£‹÷1£©‹«›€’~’ƒ‡”†˜‹§‹™ûò‹³ø-³Á÷N¬÷tûG÷7c0÷ù(š–œ• ªl‰v‰^dŠ‰ƒxjW0†ƒ}€–ƒ—™›™“–*üÉÈÙ÷~Œm„‡ƒƒ‡ƒ‡…ƒƒ‹~‹tƒŸ‹÷9¡£§™‚’‘mœ‘ ª÷†¦‹¼~£š‚€zd[ze{†jsz™†˜„œ‚•ˆwu‹l‹t|šøu“÷‡¤÷èùendstream
endobj
18 0 obj
<<
/XHeight 757
/Ascent 732
/FontFile3 17 0 R
/StemV 163
/StemH 0
/ItalicAngle 0
/CapHeight 732
/FontName/YZXDAM+Souvenir-Demi
/Type/FontDescriptor
/Descent -15
/Flags 262178
/FontBBox[-171 -283 1377 1007]
>>
endobj
19 0 obj
<<
/Name/F2
/FontDescriptor 18 0 R
/Type/Font
/BaseFont/YZXDAM+Souvenir-Demi
/Widths[340 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 340 0 0 0 0 0 0 740 740 760 820 660 0 0 0 340 0 0 600 920 760 860 680 0 740 680 680 760 0 0 0 0 0 0 0 0 0 0 0 580 620 520 620 560 360 600 0 300 300 0 300 920 620 620 640 0 440 500 380 0 540 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 300 0 0 0 0 620 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 860]
/LastChar 238
/FirstChar 32
/Subtype/Type1
/Encoding 16 0 R
>>
endobj
20 0 obj
<<
/Differences[32/space 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight 59/semicolon 65/A 67/C/D/E/F 72/H/I 76/L/M/N/O/P 82/R/S/T 86/V 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 135/aacute 142/eacute 146/iacute 150/ntilde/oacute 161/degree 168/registered/copyright 213/quoteright 231/Aacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
21 0 obj
<<
/Length1 9961
/Length 9961
/Subtype/Type1C
>>
stream
  TWGKIW+Souvenir-Light   Gø øøøø%¼û1ûa•ú_
 ‹‹
 ‹‹   ã   ß  nš  &Ú N`lITC Souvenir is a registered trademark of International Typeface Corporation.ITC Souvenir LightITC Souvenir  D  % F T D S J C  M B P E V O Q U H N G Z   R Ø  1  × I W 4 "    L  	   
 È Ï - Ó [ Y / K $ 3 5 X ¥   )   ' . * 0 ª « & 7 ¡  F   z íoÕHÊJKªLŸ'ÂgiğÙ	\

2
m
ü’®;½ªhè{³7e/´sÙ5ÎHó€<ñmó¢5çÖ*f$¸@Ş š ö!d""ı#¯$B$‚$Üûòå‹¾ù
¾äåø?ñÌùp{x‰vz˜ˆ™†˜‡ˆ|üÀdƒe~‡‡{uŠœ÷—÷å ÚÛÑÒ®éî÷bò)ÔĞ.-û/û.İ’ æŞê{NÉÊN¥-5ûYûûûWû¡òû*|Äø¼¦Û÷¡Û÷÷DÏ“Ò’Ë¤Ç¢Çµ‹Ó‹µp°h¡mf’h‹û(‹û	û‹û'‹ûô-÷‹¿‹¼œ¶¨ ™µ®‹§•‚“pi7‹û;D½İ|…¶÷ŠÅñ÷»´tVûûMy9ƒû|»ø$º´Ê÷`Ñ÷N÷·f•^š¸½½¡·ä£@‹¨œ‡®•¡Š—x–¡e`•`ac‚pjjqwdaûI÷ŸâûTSo[st’•ur–…•yŸ–€œz‹}‹€{‹~‹mªo¢}¯u±€µ‹è‹çÇ‹ğ‹¬y®r tŸb™m“ûR|Åø¼¨Û÷íøz™~£š ¥w¡w˜¡kc–eû$(û
û ûİ#÷ÁÀ¡¯³™˜¤¦Ÿ–„’|‚~ƒgm[x]*Ráåº—Æ¤³°¡²¨·»xh¦û¶‹³÷ÿØæÖ÷:÷¶•ª«£™¨±©Ÿ£vœ¢™°y£dSQ=[w¨‡€ìd}luƒ€€ƒ|€|~™‡”‡‚£scû„krˆ‚ˆ‚‡ƒ†€tŠ›öœ›¡—ƒ‚v©ü.‹³ø$³Ø÷äÖ÷øÁ­£¡®©s¡mlrukm rªÔüÁšŸ™€‚€†”ƒš¬‹›÷\°°…°ˆ‹§r€y†€|…f{†‡Š‡‹…‹—‡•‰ºƒq_ûgb…{nƒ€ˆƒ†~w‰›û|ºø!¾÷³ÉÖ÷¨ÛÉ÷gUI®_]¯Å{ÄÎĞ¨½¸¹¿›ÌÎ÷N÷ûKRk\d÷ÎœŒ¤sxZvy‚†€‡‚”‡’‰„‡jÖûÅ¹¨ÅµÄ·¯igŸ f–Ua0a$!bdŸ®ts®Š»´üB‹³ù9³ÕÖÕ÷zbz~y‚‚†ƒ†‹€w•‰œ÷ ‘Ÿ—ƒ€‘€Šˆ—†›Œ œøæœ¢sx[u‚yƒ†‡ƒ•†‘‰…›sû*|Ã÷y¸÷	»¤Û÷ÖøA÷°Ç{¾[±«bQšWb`ƒye|ƒr{xz˜ƒš—•”š«“²ÒÊ]ANL‹J€UhWjj^L+Ş\âÓÄ­Ç±rg‡y´·›£Š¢™€…”ƒšŒ¬‹›@÷$:`…hinrn_~eqq•wxœ„¡¤ó÷¬ß1|¼ø!¼ªÛ÷æÛ÷­øtûûûûû÷û÷÷"÷÷ ÷#÷û÷ û‡üRûTçñò¿ï÷÷Æ0$ZYmdbl[sXû|Äø¼÷³™Û÷«Öø	øI¦`k›Vû!1ûûûÛû÷É¿§¼±^z˜Êœ …¨—ƒ‚‘ƒ“‹›ùœ¢sx[v‚y‚†€‡‚”‡’ˆ…‡wür‹xyqq_{fûbëíç¾òô¾¨ys¶û|Âø$³ÊÖ÷‡ÖÊ÷D\Y©dg¦¹x¸ÌÉ°¹¶e˜mšÑœ”Ÿ˜€…”ƒšŒ¬‹›÷»¡´kzjƒ„|€††~”‡’‡©z†nlû;gupnjmWw_ijšª{~¤Œ«§÷’£‡ªk{D{x€•…“‡—„“‡~’zŠn‹y1‹³øÂÚÖ÷–Öø{÷±ºˆÈi°¯kX™\;XoP\£‡‡Êi{tv‚ƒ||€™‡”ˆ­€‰plû–trˆƒˆ‡ƒ†€m¢’œ÷™—”™˜‚€‚u ÷l²§©§¤§³œµè¢][û—us‡ƒˆ‡„†€mŸ’÷˜—”™—ƒƒt EûX¾÷¾øÅêÖ÷¾Û÷>÷ º”®¯¬¥¨°˜³÷±+-\€Wpdjt_rari‘–t†‚„€„~få|¤ÌÏ¨½¶¶¼™ÊËÉ{Çbº¸cS¥OB\iW]«ƒ„ÁauJlq|‹•‰¸…ˆ`hü*jˆfn‚†„‡v•‹÷œ“˜‚‚†”ƒšŒ¬‹›‹¼ø»âÖ÷6ø=Ü£Š¥§r†u>÷'™‹£vqŠcy‰‰r€T‚urw‹w‹|‹yˆ‹{‹h©‘½‹üow¬÷š›“œ¬_‚wQ‡¦½ûû`Ã÷>Á÷ùº¡Û÷ªÛø7ø9¡½ƒ¬¥pŒqZDŒ‘Kû-+ûûÜ,÷¥¥”¤µx¸uU;$‚Oi!¼”“‹““‡’‚oq^qE÷#‚»é÷8¢÷ËTµTŸÃ·¬ÌÓÎqÅ]¹û/ûí.eçÛßµğíî²05-b5!÷R‹³øÂÚÖ÷}Ö÷}Öù–÷´»†Âk°®m^œ^JMhVfÃi_«HHSiUd¡ˆ…Ílyxy~‚ƒw~}€™ˆ”ˆ°€‡dkûŠvx‡†‚‡„‡€w˜ˆ¤òœš ˜‚wŒ¡÷ˆÓÛ°Àä–BDûeut‰‚†‚†„‡€v–‰¡÷¡‘ —ƒz“Š ÷ˆÓÛ°Ä®«{k›˜q‹koûouxŠ…†„‡€v—‰¢÷ Ÿ’ —ƒ€‘€„‹š‹³ø»÷€ÎíÖ÷Aø=È¢Š£¨w‡tP÷¨†é¸––‚…“‡‘‡“Ÿ›Ÿ«lŸmKcRSzzRDŠMqwl’mlª‘¡£ûÁw`v€|„‡„†‹€v“‰÷œ› ˜‚€ƒ€†“ƒš¬‹œû>ûaĞ÷/¿÷ş³‹÷÷¢ß¹÷ß”IŸ:©P£\ºPÅ‹›‹ššyQ8 J‹y‹x“z‹x‹{z‹x‹m¨€¥‹ô‹å÷¹Ş½æ¹÷œò™à¡‘–•Œ‘‹‹˜€Œ€‹3~‚Š}f»¬‹2Ts3xWi€sJ^vr ™v¢y­€§|µsò‹µ‹É²‚‹¥‹˜€‹!{‰{•†’…~Œwu v÷•Ä¡÷”÷÷•«–ˆ¯§v‡uû>k€hn ¡ƒóç÷÷(ƒ ƒtNH_‹~„’„‘‘”•¸²ªËÇ·xºYnqvm|’z–€—€˜‹›ŒûûX¾÷Äø»šÛ÷¶Öø`øM—¦xwsl€|¨d^˜Zû#,ûûûÚû÷ÉÆª»°û2jˆqo‰ƒ†„ˆx•‰œ÷œŒŸ˜‚‚†”ƒšŒ«‹œ@÷…e‹vorqmb|d%Yåèó¸ò÷
¬®t£¨o‘he1|¼ø!¼»÷5ªÛŞ÷CÛÛ÷(÷vù‘‘œ˜•–ƒ‚eˆ„‹lŠ„‡…ˆ„{‰†Y1‡ƒ…‚‚“…”–—™‘’û…ü¸Ô÷­øtûûûûû÷û÷÷"÷÷ ÷#÷û÷ û‡üRûTçñò¿ï÷÷Æ0$ZYmdbl[sXƒöëö÷)ƒ§¥¢¨ªt£lnsuml¡sªm‹³÷…½÷ñ¿äå÷×ñ÷G÷¬æŒì“Ş´Ü³ÔÔ‹ì‹ÒgÂL«R©NL‹û˜{xŠuy™ˆ™‡˜‡ˆ|üÀc…f~~†€ˆ{uŠœ÷ ›ŸŒ¡||}všø©¦‰¢§™—¢´Œ¥¼¼‡p¶³q¥_Zû0û[^ûY|»ø¾÷—³¼ê÷Òê÷%÷ı•÷=õ÷-÷E¢™Œ¯Œ‹ ‹{|‹&‹ûSGD42dû‹û‹@•:ºM¼JÔmÜ‹÷%‹ò÷‹÷"÷9äû>ChXSŠQ¿¸Ã´Ôî¸73|ƒY‡|NyVYHHU¸Ètw¼†ÉŒÀ1‹³øÂİÌÚÖ€÷¨„ÖÑ(÷søÑ„œ’‡½­¸º—„”p“[‹Zkg¯‹abe`c€€™—“”‘š”•”˜“‡†–ûüâÔø{÷±ºˆÈi°¯kX™\;XoP\£‡‡Êi{tv‚ƒ||€™‡”ˆ­€‰plû–trˆƒˆ‡ƒ†€m¢’œ÷™—”™˜‚€‚u ÷l²§©§¤§³œµè¢][û—us‡ƒˆ‡„†€mŸ’÷˜—”™—ƒƒt 1‹³øÂ÷³ØÖ÷–Öøy÷³¿†ºg³¯jZ\OPta_÷Áœ£rx[vy‚†€‡ƒ”†’‰„‡mü¢|Œf‚}„ƒˆˆ‡ƒ‡‹‹m ’œ‹÷	™—“š˜€‚€†”ƒšŒ¬‹›÷‚´¶³¢ÈÔ´^OûYyŒi‚}‚†‚†„‡‹€mŸ’œ÷˜˜“š˜‚€‚†”ƒšŒ¬‹›ûR|³ø,³Œ÷
÷”é¥øm~„|t¥“•_¬û#ª(áû•}n‹¦‹¸Ú“š¶Ô®Ù¡ÜœÉ’¦‹’œ ’“”‹”‹Œz‹@{Šy}‘ˆ•ƒœvgg'}fw[r]la[Æ9÷D‹Ò‹Â¸‹¦‹—‚•‹Y|¿ù'¾½á÷şØ÷¡øPFœKªÜ×ÓºÒ÷,±û‹§‰£–˜‹¬ˆ—‡—„‘€’W¬D›N‹H‹N}X_]enT‹O‹û øT÷‹ûh‹"'X.‹X‹X—`§f£x©v°™ƒ‚˜zy‚{{\¾U®qeÀÎ~ÌÓÑ›¹Ä½´¬ÉÍÅrÂ]°d©Q›\–Ñ‹³÷l¿ø(³‹÷øC÷)Ş÷Pg$ƒw†…y‚…„…nº‘Åµ„¨©V|‹É®®Ş–²÷Ù’x•q¶û	‹xkX–‹lvŸ‰›÷œ¢Š¢—„x•ƒ‘ƒŸd÷ X÷5<÷R6÷%„—mÃx‹|‹u_~s;û%<ûRSû5÷÷÷$÷Ú÷ûÁ–rY‹Õù»×İ÷·êø^´•ˆ·•›‘œ’š“” ‹•‹•„“‹}‹~‚^Z|‹G‹ûk¼êİÒÜÍÛÌîÜ‹÷‹Æo¼]­]¬\•T‹K‹LzZ`chmZ‹U‹e¡d´‹£‹£—‹¦˜‚”…•š‡‘ª¥«¢¢«°—²ÓÉVA-.6LNû.û;ytI-‹qq¡ŒY|ºø»÷]Ù¼â÷Øì÷Cù'ÅÈÆšÆ¡‘Æª™‚vˆ‰û-ƒû1˜tü	Šy‰u£‹°³Ô‹õö¾;(ûB?ûV@ Ì””‹”¢v–vmyyn\­c°up¸Â€¾ÓÕºÂÀ¹«ÑÑ÷% ×ûUV|o\ûû³ù¦³ø«–C„‹r«£”›–øYù¯‘›‹Ÿm‹s‚~zû*‹³ø³÷ˆ³ØÖ÷õ÷ö¬®›¢¶—–‘‹š‹›~‹~‹û	Š}€‘ˆ“…“…’…€_ûû dmøxœ¢sw^wx‚†‡‚•‡’ˆ³}†rdü|{f~…‚‰ˆ‡ƒ†‹‹vœ‰œ‹÷™—”™˜‚‚‚†”ƒšŒ«‹œ¾áÑ®líû‹avj‹sy™‰™÷œ“Œ —ƒ‘{“‡‚œ]ÙSÖIÉ˜˜Y‹³÷/Äø^³§Ï÷”åøN÷WíŸ›¤¨{Œr.øJ§‹«es€|y4:QMQ:a@s`Uû]k«¢÷¡2^€\ƒ€‰…~x‰š÷2šŸ {Œz|ƒ…™†˜Š ‹™1÷û”À÷-ä÷ ÷÷ü.û2³ù×³°Ù÷tû&“~¥ˆ’M÷l÷÷"÷#ª÷É÷’˜¥“•z„wƒ„{tgpR{be+v'‹#‹û&´ûĞû˜s“r«‹‘‹‹•Y‹³ù2³÷«åøùY—Œ¨w|~ƒ€^j[zS‡z‰hŒ‹s‹yˆš‹À ±Šyš•}‰s{ü5K‰wB„z‰Y‹rv¤‰›÷µ¢š££_‹zŒE†šÎY|¸ù7¸¿ê÷Ìê÷Ã|÷RÈ÷z÷*ÛzïeÑÕcIÈ1ûQMû~û+û*Éûz÷Q¸CdÒÆxvÌ†ÕÍÌÔÉÈ²ÚÖÓ³@PŸL?HL†AyNNxd?@ü.û2³ù×³÷Úšù}ƒ—q„Èûªûû#û"lûNû‡ƒrƒœ‰’Ÿ“‘œ•¢¯¥Ä›³²ì ï‹ó‹÷&b÷F÷~£‚¤l‹„‹z‰‹û*|Ã÷y¸÷	»»÷5¤ÛÆ÷CšÖå÷vù‘‘œ˜•–ƒ‚eˆ„‹lŠ„‡…ˆ„{‰†Y1‡ƒ…‚‚“…”–—™‘’ûgü¸êøA÷°Ç{¾[±«bQšWb`ƒye|ƒr{xz˜ƒš—•”š«“²ÒÊ]ANL‹J€UhWjj^L+Ş\âÓÄ­Ç±rg‡y´·›£Š¢™€…”ƒšŒ¬‹›@÷$:`…hinrn_~eqq•wxœ„¡¤ó÷¬ßû*|Äø¼»÷5¦ÛÄ÷C°Ûå(÷vù‘‘œ˜•–ƒ‚eˆ„‹lŠ„‡…ˆ„{‰†Y1‡ƒ…‚‚“…”–—™‘’ûgü¸Ô÷÷DÏ“Ò’Ë¤Ç¢Çµ‹Ó‹µp°h¡mf’h‹û(‹û	û‹û'‹ûô-÷‹¿‹¼œ¶¨ ™µ®‹§•‚“pi7‹û;D½İ|…¶÷ŠÅñ÷»´tVûûMy9ƒY‹¾ù³çå÷Jù³†°™˜–œ xŒzûzx‹ux™ˆš‡˜ˆŸ‡|üÀc†f}~†ˆ{uŠ›øbŸ ‰¡•“˜Ë“–†”z{…ƒen{†[„û…UuŒ\Šx™}–£‹›ü.‹³ø$³»÷5­÷CûÖc0÷vù‘‘œ˜•–ƒ‚eˆ„‹lŠ„‡…ˆ„{‰†Y1‡ƒ…‚‚“…”–—™‘’:ü¸È÷JšŸ™€‚€†”ƒš¬‹›÷\°°…°ˆ‹§r€y†€|…f{†‡Š‡‹…‹—‡•‰ºƒq_ûgb…{nƒ€ˆƒ†~w‰›ûz‹½ø	½¡÷÷9õ÷âŸŠ“““À¡’ˆ‘ƒ~€|‚„ydkûx€––“™’“ÌŞ÷÷+ ¥ºÃ‹­ªe†vû„€zƒ„„€„_ˆ~Š‚„l‹—‹’š‘“¦±¢¸‹İ”£|}}|ƒûû%ng#û‹cj°‹£û*‹³ø³“÷÷d÷÷Y÷~ûû+woŒŒo}‡ƒ…€w‘Šš÷˜™›¤f…‹¨©ÔÛ¢£œyœyİ8‹uzr†‹yz•‰š÷™™—„~‘•{™v§~œû÷÷÷%›¢Œ¡—”’–›‚Œ{/}Š|tª‹xmE=utv¢=Û§œ£›‚Œ}û	|‚Š|{‘ˆ—„¨|™sqå|³ù/³ôÆø@Æøä÷PUãVàTÔXÏaÃû÷CoŠû~{ˆ{y‰˜ˆ·‚‹jeü[“}X~ˆ€†{{–„š÷™—’› }yn“Š˜¦ø¯÷
ûæû&èû#¸F¿I°A”x™‹§‹†­‹øÕ•Š¨•˜›—–™‹š‹œ}‘|‹û}~†zw›‰›†™‡•ˆ{Šq‹~üBûaØøÌ³Ø÷åÖ÷ øÁ­£¡®©s¡mlrukmŸr«Äû~¶Œ·…·™‰…—zz€†}„f{€‚‡‡‰‡‹…‹—†•‰–‰™ˆ’‚•}‹r‹züYŠ_g€~“‹{tx{st¤} Á»È¹£Â×ÇÑ|Äù"¾¯ñùAùŠ™‰™‚˜‚˜kœ}“OªK›H‹ûr‹û=ûU‹ûl‹ûa÷9û(÷\‹Ë‹ĞÁ­¤šÖÄ‹¬‹˜‚–~‹z€zMMNh34=ªÔWaÇwåÓà¤ÔÁÍÏÂÊ¯ãº·~p±´m›m `‘“q›‹Ÿ‹œ‹œ©‹³ù¿æå÷Ññ÷I÷Î÷6¨¸]÷û8‹TfX–‹lv¤‹š÷(™Ÿ‹Ÿ›}l™„™}ª`é]çGÙİ°İÇ‹ï‹Âo»\©^©XV‹ûËzxŠuy™ˆš‡˜‡Ÿˆ{ü¿Šc„e~†ˆ‹z‹vŸŠ›‹÷œŸ‹¡~~‘~yšø« Š§˜˜¼‹¢â÷|ûû'ûfu z‹³ù¾÷¦åø øùº‰ Ã£²†„¢°€˜¨t”ƒ–˜‹—‹‘•‹–‹“‰•‰“‰™ƒ¿‚•†„‹„Œü¿sˆC}‰Š„‰ƒƒ‘€™——™’“ª¥š´”£­¤‹¼‹†t‹dü•d‚e€}‡‡{v‰œ÷œŒ¡œ~|~xšÑ|ä÷û³÷÷sÓ÷sæ÷àøm€vŠzq®’‹b'Sû"M<l¹w¿{À|ºtÙ‹º‹³±~‹¥‹¡„Œy‹*}Šxt¤’’]š+§'³3•v¸&©‹¼‹è÷u›·š_Şûu»‹–‹‘’“¢Ÿ©™¥²Òªé¡Ú™À”¬Œ”¦‹‘‹›{Œ‹@}~Šxq²–‹X=Nû>ZJ[ØJ÷0ä¶°}¨œƒ÷*|·ø£¼í·³·÷9Ó÷NÔ÷(·³øûf÷8û?÷^÷^÷8÷?÷f÷fû8÷?û^û^û8û?ûf·÷M÷$÷,÷F÷F÷$û,ûMûMû$û,ûFûFû$÷,÷M÷bí ¨mÂ<‹_yl•‹pr¡ŒÍœ¡Š¤™ƒ€’w–Œ•‚¡vÇt¬e¼»£·¶‹Å‹­x­qn¢gh‹ûHytn{–‡˜†“‰†}ûÃmˆ}€ˆˆ‚…}o¡Îœ¢‹£}w”Ÿ÷Äª™“½…¹×‹H@ûsR‚ƒó÷Qöç÷÷'÷±¨¤¢¨ªu£lnruml¡sªŒû¹ ƒtNH_‹~„’„‘‘”•¸²ªËÇ·xºYnqvm|’z–€—€˜‹›Œü vø÷„à÷÷ùqtxpj {«Œœ†xNOg‹~…‘…‘““´®¦ÅÂ±z¶^÷*‹³÷à¿÷ ³ååøEå÷HøøEûd‚d€~‡‡{uŠœ÷!›Œ¡—‚€}‘†‘‹šø¶²ˆ”²–™–œ xŒ{û"{xŠvy™ˆ™†™ˆ‡|û‚üE÷^³‰’°—˜–œ xŒ{û{v‹uyšˆ™†˜‡ˆ{ü¿d‚e€}‡‡{uŸŠ›÷œŒ¡œ~}~xšY|¸ù4»àå÷‘ê÷É÷ÿæ†ÆJ1\yWikli[€^AL¬Û†¦‰…ll{unû÷#bæÎÌ˜µÁ¿³«ÈÍô,Ñ-Ù¡ÙÁå÷ Ìû PJxf]ptqiek£wª¡” —†š‹šÇÅ¢¿×Î\;b`nnefb‡Z‡{‰_‹r‹vŸ‡œŠY|¼ù1º»Ô÷íÔøø+Ô±áÁæöûÀ0PQyf\^imUR.ĞVÙg6i)J%û÷U÷ÎËš³Á¾±­ÆÊö4Ë/¯ûPÚh÷j!-!]9cd¢ii£s²´æÔÅØ¬ÌØG£û­äİà¼ÖÔØ]:DBZRl1‹³÷É¿÷«¿äå÷Gù!œ›•µ÷8Â²rq¤…‘˜|••’”É‡ƒ¢küOzxŠvy™ˆ™†˜‡ˆ|üÀŠc…e~~‡€‡‹{‹v‰œ‹÷œŸŒ¡}|~y›Š÷ª÷d©•‹w¡ƒ“‡—Ÿ‰§˜Œ›•Ål€‡†„ƒyu€Šoûc÷f‹³ù ³íÆø“ãø:÷zûPøUƒƒ¯rŠû|…{hÌ¬‹Pü¼j‹†l~†€‡{u‹÷˜™šz|{‘yˆøÏŸYíû†öûy‘“y›‹œ™«—‘Ö÷/÷$÷äü b“‡g}~†ˆ{v‰›÷œŒ¡||}t›øÆ°’‘­”—šš¢€zût„tx„*ûzü‹³ù ³áåáõd‚e€}‡‡{uŸŠ›÷œŒ¡œ~}~xšø¿Œ³‡’±—˜–‹œ‹ xŒ{‹û{w‹uy™ˆ™†˜‡ˆ|÷*|¿ù%À°ñø™ñø|÷n÷,÷7÷kñníCÕÓF-±(ûoûûBûg%¦-Ò@EÎågë¿;G´Ë_^ÌzÚØÖ›×´ÊÑ·ÒºßÚÔbK¹¹Kœ2=@y<_NJ[Cb:÷R|·èÆøÂà·¿¸÷ÜøQ·Àøûf÷8û?÷^÷_÷8÷?÷f÷fû8÷?û_û^û8û?ûfùEûMû%û,ûFûEû%÷,÷M÷M÷%÷,÷E÷F÷%û,ûMûYûaooyW(bìåŞ¦÷î÷z!‹³©‡¨ ‰ŠŒ­{˜g©L›^‹û‹9û‹û‹ûÙû	÷‹Ã‹ÂŸ±¹–—™ ‹‹š˜}‹z‹„‚}Ñ‹³÷l¿ø(³®÷5‹÷÷$÷C÷÷)÷\÷—÷vù‘‘œ˜•–ƒ‚eˆ„‹lŠ„‡…ˆ„{‰†Y1‡ƒ…‚‚“…”–—™‘’ûÕı»êŞ÷Pg$ƒw†…y‚…„…nº‘Åµ„¨©V|‹É®®Ş–²÷Ù’x•q¶û	‹xkX–‹lvŸ‰›÷œ¢Š¢—„x•ƒ‘ƒŸd÷ X÷5<÷R6÷%„—mÃx‹|‹u_~s;û%<ûRSû5÷÷÷$÷Ú÷ûÁ–rY‹¿÷Ğ¿÷˜¿ãå÷Fø÷Y¥—‹yŸ…‘’„”¦‰£ŸŠš’Äp€‡…„„xvxŠpûT÷JÅ‡Ÿ½÷5·¶li¦†ˆ“•‘‘•ŒƒÈˆŸƒ¡r‘üOzxŠvy˜ˆ™‡¨†usü¤dƒe~‡€‡{uŠ›øf¸Œ‡‰”¾’©‹œ‹”…“‹~‹|z‚ƒhjhuX‹û*;ƒ±İ½q³ù:³Œ÷'ø<÷ø¬ùp|}‰ykÌ—‹YMJûDsKi1f2W:WãcßgåpÏR÷3‹Ï‹«–¦™”—“‹–‹{|‹û#~xˆzl°šJ¥û­û´ ³#¼"Ë.”~–|‹Ÿ‹¨•™ç÷ì÷•²÷«÷™‘”—•“’•’‹˜‹™€‘~‹û vøVº÷bº½º÷bº÷òøìİGÏ98GG9Œ8ÎHŞİÏÎŞû‘ÃŠººÃÄº\SQ\^SR]¸ÅYn³ùÔø_Ûø_ù'û§ı
‡ƒˆ‚‹‚tª‚ÀÀµš÷røë—˜§‹– w†|ü}y‚ŒX}‰`‹{‰t¡‹ššÌ“²‰Âzœøj—÷Œ­÷Àùendstream
endobj
22 0 obj
<<
/XHeight 764
/Ascent 730
/FontFile3 21 0 R
/StemV 75
/StemH 0
/ItalicAngle 0
/CapHeight 730
/FontName/TWGKIW+Souvenir-Light
/Type/FontDescriptor
/Descent -17
/Flags 34
/FontBBox[-157 -205 1173 971]
>>
endobj
23 0 obj
<<
/Name/F3
/FontDescriptor 22 0 R
/Type/Font
/BaseFont/TWGKIW+Souvenir-Light
/Widths[300 0 0 0 0 0 0 0 240 240 0 0 300 300 300 520 600 600 600 600 600 600 600 600 600 0 0 300 0 0 0 0 0 720 0 720 740 600 560 0 800 260 0 0 600 860 740 800 620 0 680 600 640 0 700 0 0 0 0 0 0 0 0 0 0 500 520 460 520 500 300 520 560 240 220 500 220 840 560 560 580 520 360 400 300 520 460 720 500 480 420 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 0 500 0 0 0 240 0 0 0 560 560 0 0 0 0 0 0 0 0 0 400 0 0 0 0 0 0 800 840 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 280 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 720]
/LastChar 231
/FirstChar 32
/Subtype/Type1
/Encoding 20 0 R
>>
endobj
24 0 obj
<<
/Differences[46/period 97/a/b 101/e 108/l 111/o/p 114/r]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
25 0 obj
<<
/Length1 1099
/Length 1099
/Subtype/Type1C
>>
stream
  OQGELM+Souvenir-LightItalic   Mø øøøøé¥ÿ$¼ûTûaïúZ
 ‹‹
 ‹‹   ë   ç   üš  < C\hITC Souvenir is a trademark of International Typeface Corporation.ITC Souvenir Light ItalicITC Souvenir    Q S P C B M F  	   «YÜKœ*ûòEûUÜğ¾øÆ÷ Ú÷›ä÷)ô–Ï”Ó©Ê¥Äµ¿Ï‹Û‹®K‹A‹#Pûû‹_‹m¢‹‹…t‹‚‹fÛ†¥‹÷!‹÷÷1‹÷÷Jàû)UO5i”¯¯±šŠ xvWm€x‚†}…kÃ¦Xo†n‡p{û sû$sû†w„„x„~†|†z{Ÿ‡—÷™™‘›¬bw‹¶­’¯¬û‹³÷÷Ü÷×÷
Œ’Œ“ÚÀ÷¶ñ‹£‹˜t ‹¦‹‘©‹¡‹ª} i‹`‹]lpkpj~e€c•“â‹¤‡¿h‹zBdvnÀœ‹NX|@Wy0‰~…p‹~t™Ÿ1€¼ø»â÷Ûá÷y€÷*÷÷÷,÷.Ûûû)ûûû*û
ê7÷”¼3^ÈŞ÷	Ğ÷÷à¶D=û Bûûû€¾øÈ÷„³÷"ä÷XŞÇò‡s€]tƒ–œ¬±™–d¤»{·÷,÷÷)÷'öQàûDVfSd›«÷K’²™Ô‹±£†‹~v`t€zƒ|„{p°˜do…n‡nSûø÷…÷oŞ¦BC$JûûHg¹ËïÀ÷:÷û€Çø	ÁšÚ÷¹ø^øJŒŒ‘“†“‚tplz~°ra_û)û û4û)Á0öß¼ÉÒª…4‹{p ‹ŸÙ°£ªYl‹Á¶™Ú’¸û€ûuDqÒÈìÅ÷$÷Ä¯cS,[ûJûƒ³ùA³Óà÷iøU¸÷–•“‹–—‚”p6dl€—ˆ“ˆ›†’ƒynS‡l;ün‰‚‰}‹‚~šŸŞª¥£hx‹µ¡¢ û*€Èø¸šß÷´Ü÷d€ËÍ£¯¿›–´§£”ƒ’rV=‹û/P¶í“Õ’Ù’Ó¤É¡Ş»‹Ö‹¨z¥tœl¡_’g‹û,‹û*û"‹û.‹ûÚ?÷‹!÷Œëèíë­´x`-ûpeFƒ÷Àóìƒ®¤©­£z¢rgqnhqœv¦|šøg”÷”¤÷Àùendstream
endobj
26 0 obj
<<
/XHeight 757
/Ascent 732
/FontFile3 25 0 R
/StemV 79
/StemH 0
/ItalicAngle -9
/CapHeight 732
/FontName/OQGELM+Souvenir-LightItalic
/Type/FontDescriptor
/Descent -15
/Flags 98
/FontBBox[-192 -205 1263 966]
>>
endobj
27 0 obj
<<
/Name/F4
/FontDescriptor 26 0 R
/Type/Font
/BaseFont/OQGELM+Souvenir-LightItalic
/Widths[300 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 520 540 0 0 500 0 0 0 0 0 0 300 0 0 560 580 0 400]
/LastChar 114
/FirstChar 46
/Subtype/Type1
/Encoding 24 0 R
>>
endobj
28 0 obj
<<
/Differences[32/space 44/comma 46/period 49/one/two 58/colon 65/A 67/C 69/E/F/G/H 78/N 82/R/S/T/U 97/a/b/c/d/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u/v 121/y 146/iacute 151/oacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
29 0 obj
<<
/Length1 4731
/Length 4731
/Subtype/Type1C
>>
stream
  FUJGQA+Times-Italic   Cø øøøø€û=ûmú…ú
 ‹‹
 ‹‹      ü  O¬  Z }‰002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku  &  5 P M Z Q D B E J V N  O G U  H S W T  4 F '  Ø / Ó  ) ( 6 & I " 3 C  $ (   Y  ëxùFÀK´D	
œ«Oµ$”À	G	§
 
t
ê_ã9ĞC·;Î2´Z·- vøÿ®ÆøÑùù"ü§aû.‡¡ºœ¤¥Ÿ¤¬¦‘÷û#ü¥}YszF„{÷¶›9‘‚«•‘¥’¥÷ ø‡ÁÖ¨rKŠ‚‰xœŠû*•vøYv¦ß÷¦Şøh÷¹èUÃ2û(û*û0û-/ÂWë÷ ÷*÷<÷8«)Bûmû[k°Âîİ÷p÷¶§fPü•v´÷‚÷«ù;†Q{ˆ9{¤·Šr„–v>"üv;ˆ}‹zi›yªÁ§¢ñÑ”UCwxu‹†‘•’š“©ûbûLvùv÷àéc³Ğø>ø²u£hàv{|wĞZÁ—‹dP,û/p]w÷…¬N÷qy‹vE}VzŸ“Œ”Á¤Yûl¼šG•V~{„|tmxqplww€…‚‹w‹}¨p‹t‹z{‹u‹pŸyª‹°‹¼²Ğà÷	÷#÷÷ƒ‹Úû*ûMv÷Wø¶øåøi÷Éßa¼BL[l=T‰§î‡’û0uz©­ˆ‹p„†s‚jûüN~Y……[†|÷bš\y”¡©¨ğ“®}¦˜ˆ¨÷!÷0÷=÷+1“û(û û5'ltš¡¹»÷(¹Ì¤Ä¼¿³¡mWûb€¯ø5w©àø<÷ü½a«Hû%û û'û.)¿UëÔÉ®ÔÀ{”cZSk[‹Sh¸Ò÷$ì÷ñ£šƒ{|‚‹ru›|£¦¥û*€¼[»ø¡œŞğøpï–~~YSy‹„†“•¦–µØ÷Æ…L„€[ŠŒ€®od‹ûû1ûJû-=®bÎÑ²©÷ãˆ{L†q‹wğo˜¨±¬¥ßÍû÷”3,ûz!dr§·åé÷q÷®¢qdû*“v»ø¢šáğø¢ù;†Pw‰B‚y¿–‡v‚†rg_û3‰‰…³zšb‹û û,û`ûB²^ËĞµ©ìÏ‰‚eˆv‹uğmœ{©°¾´ÔÀ•]Vwy|‹ƒ”–“‹Œ”­ğ{÷û" ûD4dt¦·çì÷o÷«›uaü–vøÄõ÷;ì÷œøï©v¢povtmm t§¦ ¢©nüˆ~–j]jly‹ƒ…‘”’‹šÂä÷ÖˆH~sˆF‚{¿Š–‡y…ˆ{†ydû$lûŠ…‹re›x©¹³«ÜÁû*€ÀmvøNvªv÷à÷¸øo÷ }”[Nyy|‹„…‘•—Œ˜¼‹ Ù÷¼AaûrT`HP/XUn‹q‹¥“æø ¸ˆQ}zˆ@€} ‰²’lƒ‹Š‚gYûW\†p‹zgx¯Ğ¾¾÷O÷hûƒhwølœy©Ï¯Ğ»®Ó—v©vø¿\º—ùFxùRô}—ZOxyzŠƒ†•”Œ’£Ä÷g”­‘©‹˜¯s§k24ûHa‰¦ã•±‹œ¯t£iO?Dû8ˆÄ÷[ˆ$vŒŒP€{ÀŠ–‡zƒ‘{M8ûÊÖªğŸßÉãxÑ¼Â»¨˜“‚|ƒŒ|T‹‰;ûº×²÷, Â»ÏºÏÁ»¦‹—‹”‚‹}‹†Œ€^ZûZ}Q‡z~øoš{¦¹º°ØÀû*—v©vøNv™ø`ğønó|˜UFy‹‚…’”’ •±·÷4—·”´‹š°q¤e,4û&H^‰Ë÷e‡ût‘Œ[‚{¾‰˜†x~‚n…v‹ƒl@û§Ö´÷$¢Ã¼ÑÊã±¬¯‹˜‹•‹z‹€…lf`û7{PŠƒ|ğl›{«¹©¤ãËüûMvøï«÷x¡¯êø:øú±g¦Xaexdjibu\j#0ƒkå3ü9tûlX_‹„‘•””‹™ zšsw}zsi¬q·åĞì÷MµÔ÷Õ÷ ‘« ÷0¦±ÓÂ™•†„Š†€‹|sš{¡¢¡ü–vø+¬¯÷˜÷¼øB;§òŒ‹‹ˆ……ŠŠ€‚\Sbib{m€‡ˆ‹‹‚‹”‹‚ÖBû§t5Œ‹‚uŠ y¦¤£–Ÿ¢›˜œ³Ä~‘rlpj{}‹…‘–Œ›ß÷Òß€÷¦÷÷·ªr¤mlrrlm¤rª©¤¤©û*ûLv÷ø¡÷‹¡“Â¬Ú÷*ÈjÚüølø³Ozv¯‹; 0=/U nÅpPcyxt}’€|\gFoGHÍ]ë÷ŞÃä÷ûj{‹À–£¨˜™š†‹™úâèßØ˜Šƒ±E}.R5Neu§¼æÄÚÍ®Ÿr`üoüMVQa?>X²Æ¯–¢©¤œŸ˜“Êr…šÓoŸxdû™ v÷èñŒv¸øğø0øªxŸnX@7(^‚wŠ¼÷[ğˆWW‚W‚{“Œ“ ˜y~…ih:û¹×¶÷ š´®Ğ°ÕµÀ ‹ğ f‹¶¨œ«ûbvø_v÷àèY½Ğø=ø­s¥kàu|~wĞ^¶‹h`JûB@lk†÷‚÷l÷
•ˆˆ‹…~z})}¯Œ¦“š^›[›û0û+Œn‹Š”‹‹ÎÙ—˜÷÷Ô÷‹Éû™“v¢vøA£Œv÷ Ô¹Ø|øøO}}‚„‡~|nqœ‹cC[aJ-÷?‹@[nkaRl³ìz|üwû4š›’‘–|­ªx‹±ßÉÂÖêûÙ‹Ô¬¢Ÿ­½«g=•|›‡÷÷¬³s§invxpz’{š}ƒrurVg•xà¼¶Á‹Æû*y®€vù¬Œv÷â÷ã¼øù0ty€~ƒy¼fz¤‹>ûDD*P—r÷ûÂQ›q]@SQB9KÓè’‹‘—wŒüjûsœ£’—•¼µÀf‹Æ÷äá÷Ít²/ç8Ş{¥¸È¶µÊã®^û	¼œ‰ûb¸ø¢ªá÷yÌø/ø
¸o¢Tûû2û9û&3¾VàÎÕ²ÏÉ—CQk{`‹Se°Á™Ÿ’¥¨÷, ò×‹âJ’7+Gûv·°æÏÔÀ Œš{td v÷Û®÷—¬“ùùù"ü†{Ï…•†n}†p…tûüO{Rƒ„R€{÷›Qy–¨–Œ“©É÷sÅŠÁŠ¹‹Yx‰|…sœ…×÷x‘Z,“ûBˆÌ÷}‘¢•Í‹÷,ª~M}‹‚‰xŸ‰û* v¼÷üø-ù0‘‰‡„2v{+{ ¯‹‹£Œ˜€xƒ‹……wûü‚€e‚‡0}÷«™tŒK‡°’‰ƒ Ö÷#øšš”‹û*•vøYv÷†v¦ß÷.÷s$Şàèø'ù {šw‚‡……û6û4®÷@ö–’”‹–ü|ıôøh÷¹èUÃ2û(û*û0û-/ÂWë÷ ÷*÷<÷8«)Bûmû[k°Âîİ÷p÷¶§fPœ‘v¯vù"vwùğùkù›û[{Â‡™j}Š…‚h&ü‰ûdøƒû3{¼‡™‚¢aûü7hû}Q{÷[›U‘z•©•¤œ÷ø5ğ÷yü¶÷$ø¯÷‘•É–ü–vøXv÷†v¼÷N&÷s]èø'ù {šw‚‡……û6û4®÷@ö–’”‹–ûùığ÷ò~–j]jly‹ƒ…‘”’‹šÂä÷ÖˆH~sˆF‚{¿Š–‡y…ˆ{†ydû$lûŠ…‹re›x©¹³«ÜÁû*‹Öø¥ÔøàøWøíFÔ-*?Q%gŸ„²Íµ§É‹ÒÀWDP`C%ûûeûtz÷÷½÷z’rXv~U‹ûR÷U÷U÷
÷
©º‹ÏÓ v÷Úµ÷²vƒù™ù‘ù›ûŠ{Ë‚‘„p~†k†z\û9û°À÷X˜»£Ë“›û¦{—Š”Š‘Š±†˜€‹s‹}‡p…vûüO|T„…Q~{÷Š›R’|”¦’Œ”’Î÷ˆ÷±Jû€}Xw}H‚{÷¥›J‘}’§’””÷øvšÄ“’Å•Óy±øø®¿÷øåùe÷ÃœûzÊ†š„shfûyolwe|Sû?Ó÷÷=ğ÷…÷ZôÍR!“ˆ¼÷Y|~uyo‹fK­‹@ûgûVûZûkû8÷û ÷EÜÜ¡³Ğ»÷O™Â›—ÎÓyµù
vñæùù›ûY{Â†šl€‡z€d?û¯cû*IGû ‹9R»Î¿¨é™¾Ê÷ušÁ¢œÊ‘›û¥{Ñ…”‡p…j‚lRû`_w8‹`)æD÷÷ŞÓ÷*·ß÷±²÷È˜d‹¬÷¹®÷˜¬Šùùù"ü„{ª‰¸Œa|‡q…vûüO|VU€{øÉ÷7z“<ûSqû9‹Xs–¢• —¸¾÷NÉˆä‡—‡‹hƒŠ~‡i…Ï÷}y_+Š‹û@‰Ì÷}’£”Ì‹÷0§Hƒ‹‰x ‰û*—v©vøOvø]ğøpô—_Qvwz‹ƒ„’•–‘™“Ä÷e•®‘©‹˜²p§fKFMû#-‰÷
øK…L}w†Bƒz¤ŒœŒ¤‰‹tuj|Pûü‹Ö±÷)›µ²ÆÁÜÍÆ®‹›‹—€‹}‹†Œ‹ƒnWûS}W‚ağpœ{§¾·®Ú»d v÷v¯ø+vXøûøÈ›Sƒ•Ó,øÌqûµü‰Aû}{bƒ{÷O›\~’¢˜“¥—¢Å÷÷pŸûŒŒ‚‹gx~PŠ{¾÷šûV÷(÷˜d v÷â§÷›¨øuôøŞø”èC¼ûû{ª†´b†n…wûüO{Qƒ„T‚z÷‡›T~”©—“©Ä÷eË†÷ûÙ÷(›_xw¿.÷‰÷¨ËÄç"&KUû	s„ŒoÌ÷y‘¡˜‘°‹ØµdFû*¡ø¼øàøn÷ÔÔ[¼D2V:J^Šğø†U‚‹#|{ ‰¸‘nyf‡{ûüŠˆrÕnÉ÷)÷:÷B÷06~#ûûSûh|—¦ìë÷‰÷µ§iWûÑ€÷÷|÷½÷€÷Ğ÷™øªr¤mlrrlm¤rª©¤¤©à'ûëªr¤mlrrlm¤rª©¤¤©œy¸øò®‰vÍ÷ğùEù.vz‚†vğjf£‹4ûgûVû[ûlû5õû÷0ğİ¹óäz™WUEJû ‹ûM×÷ ÷8÷÷v÷RçÀS!”ğ‡xøA™÷g¢’‹÷¡üs¡
¢
_÷ùendstream
endobj
30 0 obj
<<
/XHeight 677
/Ascent 684
/FontFile3 29 0 R
/StemV 23
/StemH 0
/ItalicAngle -11
/CapHeight 654
/FontName/FUJGQA+Times-Italic
/Type/FontDescriptor
/Descent -205
/Flags 98
/FontBBox[-169 -217 1009 884]
>>
endobj
31 0 obj
<<
/Name/F5
/FontDescriptor 30 0 R
/Type/Font
/BaseFont/FUJGQA+Times-Italic
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 0 500 500 0 0 0 0 0 0 0 333 0 0 0 0 0 0 611 0 667 0 611 611 722 722 0 0 0 0 0 667 0 0 0 611 500 556 722 0 0 0 0 0 0 0 0 0 0 0 500 500 444 500 444 278 500 500 278 0 0 278 722 500 500 500 0 389 389 278 500 444 0 0 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 500]
/LastChar 151
/FirstChar 32
/Subtype/Type1
/Encoding 28 0 R
>>
endobj
32 0 obj
<<
/Differences[32/space 67/C 97/a/b/c/d/e/f/g 105/i 108/l/m/n/o/p 114/r/s/t/u]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
33 0 obj
<<
/Length1 2228
/Length 2228
/Subtype/Type1C
>>
stream
  ROZBKM+Times-Bold   @ø øøøøû<ûnúzú:
 ‹‹
 ‹‹   ù   õ   °   }‡Œ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku    $ F G B M  T P D J E Q S O V U H N C    g Ï/ºéêc«ô=¤~ã;y7ØCÒyºù	­‡w¼÷EûEù`¤ôùA÷m¤;4Ig;‹ûIñ÷a÷kÈö÷çÛEûÇ¤ô÷~pk~}yèoB½‹#ûVû)û0û`ûd÷%û"÷j÷Î®÷îûc}Ó÷O°÷4©¤÷$û$÷÷÷ôø<÷t™aXo{_‹BcÊ÷†÷÷*„JØû	û6'û û&İ'÷ŞÁ­æÇìû÷?û÷ »½¥Ÿ{l’‘u‹ƒ8ûÒ‹¤ø¸÷zwÑ÷Ã÷øøäÅP´7RYwjomh‚a'S^Ãûà`€^‡r÷©¤IŠ{šË÷Íá¸5÷Á™¢¬˜„‚Šzvz‹qm¥s«³££±û+}ÒZvø[ª¤÷&û÷÷÷¬øz¶} ˆˆ‡Š†‹~„”›÷™à>¿ûû>XBa£rµ²§¢«µl“‹©œ­Ä¤pMB´1qûE^û	N¹^ÊÅ¹Ÿ½ÂìX•¡y¿µ¦™µ³´ûVÄjn{qou¨²Å²²İ£ü	‹¤ùwÍ÷÷‘¤kŒ{Ÿ±øäûQr¯‡™{eü‘ezwjŠrûš}­vøY¬Šw¤¦qï'¥÷gì¥÷ü÷÷?û~r‹ñªª¥¬Ä´f>¤¥µ÷&t|†…†}¥tk ‹X.IO8û3÷’‹.emp_£F]·äuépû:¤ ””’‘¥Än‹ÀçÌÈãû+~©ø=©¤÷'÷1÷&øo÷y÷ ,òûû,$û û!é&÷÷éğ÷!û&Œû3wUPQwÁ÷3÷2ŸÁÅÆŸUû2ûc~Íøª¤÷!øAæyfbp|c‹7Rä÷õªÊÀ«“€UŒSŒ›u²µ¥¤²ÉG»3û)"û&ûä)÷×Í®Ğ¼ü	‹¤øHw÷wÏ÷÷jøúµh®a`hha`®h¶µ®®¶²üú¤j~›¯øûSs¸€’„aû¹bƒƒ_r,}Ãø
Ã÷H£¤÷(÷6÷ø©£_|™´øÓûlsÎ†•„]ûL¼\r˜^û:!û$û×*÷ ¼¯»·JĞ¦î•ûZè{aUbUrÅ÷÷¦ÇÃ­ªsf™,ûLv÷TÂø
Ã€wÕ÷ ÷5÷'ìø÷‡÷?ë!MfsUpˆÜÎûRr·„”aü‰b„„[‚s÷¤ PyŸÍ÷!]º¥~¶÷Øò÷-û'wûpQQjrŸ³y÷‡ì•¬È¿¿£Nûûc‹¤÷Â÷%5á€wİ÷û÷ ¨øEøºj©Y[anNc‰¸ÚûQr³‰˜|bûºd€aƒr÷¤¤N€˜É÷P¿¦¶«ä©P‹Á±¥¦´,‹¤øÎ€wÔ÷÷÷Øø­¤h}œ´÷‹ãXÁ8U`tU^øÍûSrµ…•dû»c€~b…r÷ƒ¤i}›°÷Ø’±¾»­oUû†f€}g†r,~Ìø¤Ë÷÷÷øªŸ¢b}šµ÷ûû]r¿‡•^û®ifz‚od{Ÿ¾÷æûOr´ƒ’‚aû2¼XâÅµ§°µJÉ¢ÌÌ‘ûÒ”vøA·Ó÷÷ßîr—sa€v‹q~±÷Áç·/÷=r?&okMUq¿ûØI¶dÒÌ®¥à¸û+ûb«÷÷ã¦÷kÁ‚©§ã<÷û÷÷+÷fÚé@øvSÙO¸#J=v“©¢©¦¥Êò€ïÎÅáµ€§n§ÛÁûê@œXveû8J-G¸SØpŠé@;mfeXc¤q¿}Šì@Q‚jqeQ×g÷÷>á½ïê€ûEø/xg\^w²äé±º¹d.ì@íü1^Tq)5[¢¶¢”˜¥÷@Â¤{i÷I‹¤øÎIÍwÑ÷û÷÷÷÷÷«ù¾¤dŒ€˜µ÷áWÃ:QctKYÍml FMdsNbŠ»ÔûRrµ†—~cûºb‚_ƒr÷¤§j~›±÷”´¾·°œpRû…a€d‡r÷~¤i~›±÷ç”´½¹®šrQû…a€~f‰r,}«vøDÀ÷`wÒ÷û÷ ÷6÷&zø›÷†÷?éû[k}bb÷—ûUr·„•€düó—ÚÃö`¾¬}½÷æó÷,û&{û$nKIen­·÷›´š¡«È«Hûxøa—÷_›÷p”÷Ÿ“üu¤
¤Œ
_÷ùendstream
endobj
34 0 obj
<<
/XHeight 921
/Ascent 912
/FontFile3 33 0 R
/StemV 25
/StemH 0
/ItalicAngle 0
/CapHeight 676
/FontName/ROZBKM+Times-Bold
/Type/FontDescriptor
/Descent -203
/Flags 262178
/FontBBox[-168 -218 998 934]
>>
endobj
35 0 obj
<<
/Name/F6
/FontDescriptor 34 0 R
/Type/Font
/BaseFont/ROZBKM+Times-Bold
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 721 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 499 555 443 555 443 332 499 0 277 0 0 277 831 555 499 555 0 443 388 332 555]
/LastChar 117
/FirstChar 32
/Subtype/Type1
/Encoding 32 0 R
>>
endobj
36 0 obj
<<
/Differences[32/space 46/period 73/I 84/T 97/a/b 108/l]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
37 0 obj
<<
/Length1 707
/Length 707
/Subtype/Type1C
>>
stream
  FPUAPO+Frutiger-Bold   @ø øøøøû:ûú|ú;
 ‹‹
 ‹‹      +Ã  ‹ •¥­Copyright (c) 1988, 1990, 1994 Adobe Systems Incorporated.  All Rights Reserved.Frutiger is a trademark of Linotype-Hell AG and/or its subsidiaries.Frutiger 65 BoldFrutiger    5 B C M  *     $ ±%&:Lü- vøà÷÷d÷ ÷d÷ øà÷\÷ü°û÷\-í5á÷,Û÷í¯÷÷c÷û÷
|ëø	­¸Ä¡ÄÚ°o8ASI†rXXrf^>Š)äTæÈÎ«ÄªBŒ{‹ip\÷
ˆ³‰¯Š²Š±Š²‹¿Í÷,JÌû1RE|sW¬ÓûçÚä•ÇÅc…funovkyb[f·dó/çn¨÷ßó÷swĞ÷÷|÷ –÷`÷—Ó­çáâ£,FDr+32néÔDûû—÷$ÊT²ÉwÄ÷2Å÷÷!÷"Q÷û2E\nZf‰÷Áû vù‚wÓ÷Ó÷ù‚û vùNwĞ÷ Ğ÷ ùNû ‹÷ Ğ÷ Ğ÷ ÷ û —ùN—ûW—÷s—÷¨‘ñ“üú——ùN—û\—÷x—÷¨‘õ“üş—	í
÷ Œ÷ªùendstream
endobj
38 0 obj
<<
/XHeight 762
/Ascent 750
/FontFile3 37 0 R
/StemV 140
/StemH 0
/ItalicAngle 0
/CapHeight 698
/FontName/FPUAPO+Frutiger-Bold
/Type/FontDescriptor
/Descent -210
/Flags 262176
/FontBBox[-166 -250 1000 935]
>>
endobj
39 0 obj
<<
/Name/F17
/FontDescriptor 38 0 R
/Type/Font
/BaseFont/FPUAPO+Frutiger-Bold
/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 556 0 0 0 0 0 0 0 0 0 0 0 0 556 611 0 0 0 0 0 0 0 0 0 278]
/LastChar 108
/FirstChar 32
/Subtype/Type1
/Encoding 36 0 R
>>
endobj
40 0 obj
<<
/Differences[32/space 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six 56/eight/nine/colon 65/A/B/C/D/E/F 73/I 77/M/N 82/R/S/T 97/a/b/c/d/e/f/g/h/i/j 108/l/m/n/o/p 114/r/s/t/u/v 121/y/z 135/aacute 142/eacute 146/iacute 151/oacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
41 0 obj
<<
/Length1 4279
/Length 4279
/Subtype/Type1C
>>
stream
  ZTOKAW+Frutiger-Light   @ø øøøøû,ûú|ú#
 ‹‹
 ‹‹      Ç  { •¦®Copyright (c) 1988, 1990, 1994 Adobe Systems Incorporated.  All Rights Reserved.Frutiger is a trademark of Linotype-Hell AG and/or its subsidiaries.Frutiger 45 LightFrutiger  6  $ B T P  D M Ó O J E F G U Q S V 4 H      ' 5  N  % È C . W  	  
 I Ï [  Z K Ø   3  " * / & #  8   M ¼]^¤·é*L¬ü@€ã!eÁANdŒÄPqÜF]›'‚½æ	W	Œ	Ò

?
®
Ô
ë/kÕ*æVŠÒ÷[züœÇøîÇÄĞøÍù@g8’bûlûû)ûhûl÷û%÷p·Ù’¢±‡ÇcsE…]‹ûL(÷÷D÷Añ÷÷I¼Ê„t·û*Áaµ÷kÁ÷1Á³Ğ÷•Ê|øÉ†®‹ª´÷u÷VÄû^I{xdN©º½—Ààª_4qûûJƒû?¬]¢)÷%ÊÒ¬È§…÷$Tˆûû(Q[¤Î÷÷–÷û™Áø>Át¢´Ê÷JĞØ­—y¸¼…¼Øğ°÷ ÷;û‹êÌ¸ŸÌ®¸‚|¬(‘ÂØœ^U‘p79e&û(÷‰‹ûQVjOZ]˜e-Áø>Á³Ğ÷æĞ³÷“ûÔû÷9÷9Ô÷÷÷B÷û9û9BûûĞ÷
Æê÷÷Æ,û
û
P,ûûPê÷
ûbÁø>Á´Ğø4øŠ‘y_™Nû+&ûû1û"Ûû÷8»³š¶…Æe}f‚c‹ûEì÷÷Ğä÷­´€|­ü@ vù‚wÚÊÚÊù‚Lü@ vø’wÔ÷$À÷@û&Ê‚0ÀøĞ¹÷÷$<û&ıWÈÚÊø’L- vøhµaÁÚÊ÷¤Ê¸ÚÊ÷®à¯ğ÷â­M+ûÊÊ÷Ú÷[ßû!eR]v‰PæNb‹cdü@ vø’w÷0ßÚÊğÚÊø’L0Ê÷pL7Ê-Áaµø>Á÷xw¼Ğ÷ÂÊ¼øwù‚LûÚ‰¤‚YÔ'û*Oûû/û+Ñû÷ Ô¿§Ì­D:Ê¬ü÷“îª÷÷÷²û..dûûûl÷îû*Á÷WÁ÷EÁ´Ğ÷¬Ğø9ÛxmHx]ûQâ÷ ÷ñ«÷P÷û$û5ûû0û-Êû÷=ºÄ•·ûË÷§ßÄèèé¯32ûÑ vø\Á÷ZÁ•÷Êè÷Êø\÷Áû·È‚èá‡„˜Âh’pwû‡û  f$UòûÑÁø2Á÷Ê÷¿ø’û÷%Luû'Uïû¾.>÷ªª“‘š‡¿y„{†s‹Xz±¹÷Ş÷-ûQv÷ZÁø>µaÁÔÊ÷ÂĞÜÔûfÊ÷½Iª»jÛ÷ Ñ÷÷+÷/O÷û*û d>o{‰(èL\øû“(lûûûd÷èè²÷÷÷ªû(ûÑ vø\ÁUÍÚÊĞÚÊ÷0ç¦÷ï›œ‰‡˜Í€y|J`VRt‰PíLf‹vS-ÁaµøhwÚÊ÷¤Ê¸øqø’Lû®6g&û4iÉë÷ÊLûÚû»7÷õ±Ä¹ H0È‡´‹³²û*ÇøîÇt¢ÅĞ÷ĞØÇ{°À}Ï÷ ÷Ã÷!÷`ûÔŒ‹÷ åÚ©Óº¼‚zª(–ÊØ[Tiû)EûûK÷Ôz‹û(D_5J[š¥b-ûlÁp¦÷6Áø2µaÁ¼Ğ÷ÂÊ®÷
÷“îª÷÷÷¯1û.bû û cğïø÷“L®Q‰È\_”Gû*Oûû/û¿û"÷7ÌÃ¥Õ­û$}û
û6TS›ŸdD†L†ƒ¥ÈxÎ÷CË÷÷"‹ßíÜíÜß:û÷nÁ÷"ÁûÊÚ÷n7- vøw÷Ù‹w÷¦ĞØ÷øÊ±^¨÷îı ĞùNM- v÷5Çø,Ğ¢Ê÷¢Ğ÷ø÷qû¢÷ ø,ûáüh÷áû5Ğ÷5òÇ$øq3ûÎüi-„Ç÷øv÷•Ç¹Ğ\Ğ÷­Ğ]Ğ(Ïø²/ÎVÓi’0jE_ û÷Q÷÷÷¼÷÷D³,­$Í¯ØÄá÷'¼û(6û]û	’ø	ûù+:g9;8»Ùìİ§Ü¬Ëjîl3lûÄ÷óÔÏ¯ÔÌÖhAC>^LlR§7³Ûûb v÷İÇ÷ÇØĞØĞ÷İ÷Çû÷÷›Çûàû* vùÇ÷lĞ÷lĞù÷bÇüuO÷b-„ÇøäÇ¼Ğ÷ÔĞ÷ªù÷%šûHûû|ûHû%û%|÷H÷÷š÷H÷%ÇûN`ûUû7û&©ûf÷[÷[©÷f÷&÷7`÷UûN÷K vøhµaÁÚÊ÷‰Ê÷‰Ê¼ùŠ÷óîQÓ$;O[Ot‰ä{A^ûmKhw‰ŒÜáNb‹cdüÊ÷®¼÷ÏÆĞÜ¦RCûçÊ÷®÷ÏÆĞÜ¦RCûç”vùfwl÷èlĞ÷£ùfFœ‹ÇøÖÇÛĞøĞ÷)ùğ÷0÷Dûiûjû;ûZRFO÷÷{÷=ì÷‘÷`(÷$ûûAû*Áaµ÷kÁ÷1Á´÷$³ĞŞ÷@Ê÷‚
ÀøĞ¹÷÷$<û±ıWuøÉ†®‹ª´÷u÷VÄû^I{xdN©º½—Ààª_4qûûJƒû?¥]¢)÷%ÊÒ¬È§…÷$Tˆûû(Q[¤Î÷÷–÷-Áaµø>Á÷xwÔÊ÷ÂĞHÔÊ¼ÜJ­¿oÔ÷ Ñ÷÷+÷/O÷û*'YBr‚‰÷ÚLøüƒ(lûûûd÷èè¯÷÷÷ªû(÷ƒ v‹ßøµĞáĞø×Ğ¸áĞù	÷šı	Æ÷’ù	ı	ĞùN(pû”üúû“øú ûb‹ĞøMw”ø>øGø’Iû(üM‰û!øMF÷Aü’Õ-„Ç_·÷`Ç÷ÜÇ¼Ğ÷ÎĞ¼÷©ùUû#6-ûûA÷^çÌÊ¦Æ¯û"Sû+ûIc]”˜nH…IŒ‚°°„±÷€Ú÷>÷g¼÷8d÷;ûM€ü*XÈñéÂÒñòº45/PL' vùˆwµÊ÷“û B÷ >÷&÷6÷6Ø÷&Ô÷ a4û7û#û<û<ßû#âû-‹ÇøİÇ½à÷‡Ö½ø7Çûâ÷÷åîñ÷‹ó÷2ÄûRGurX—LÂ«½Ê‹ĞÁWA67#7.û4ûE vùˆw÷AÊ¢ùˆÔû Øû&û6û6>û&Bû µâ÷ß÷#÷<÷<7÷#4÷- vøhÁ÷xwÚÊ÷¤ÊÚÊ÷¥ä²õ÷óœ?3ûÄÊ÷Å÷fæû@RaSp‰÷ÚLû*Á÷WÁ÷EÁ´÷$´Ğİ÷@¥Ğ÷‚ÀøĞ¹÷÷$<û±ıWêø9ÛxmHx]ûQâ÷ ÷ñ«÷P÷û$û5ûû0û-Êû÷=ºÄ•·ûË÷§ßÄèèé¯32ûb‹Áø&Á«ø«øÁûÇ÷Çø&ÁüU÷»ûÇü'ûÑ v÷Ğ´÷´÷÷ĞûûbûlÁù4w”ø>Ùø’F÷Iü˜~^wIy^U‹t…U †£ˆ¢‹Ò¯ÑÑ£÷`øŞIû'ü=Šü@ûlÁù4w÷0ßÚÊğoûg‰•ˆ¦ç¢ÉİøÚLüÒV†^Kz‚0÷>ú
L7Ê-Áø>Á´÷$³Ğ÷÷@ÂĞ÷;‚(ÀøĞ¹÷÷$<ûÍıWÔ³÷“ûÔû÷9÷9Ô÷÷÷B÷û9û9BûûĞ÷
Æê÷÷Æ,û
û
P,ûûPê÷
-„Ç÷ĞÇ÷eÇíĞ÷‘Ğø^ùNûù„ûó¾š´’Æ‹÷
ÄYû û-Z0ZS—£_Dyº¿„½÷)ôÙ÷.÷7×ûUn„ƒt÷t÷µ-„Ç÷«Ç÷‘Çø)Ğ÷*÷àËÖ÷û!,b7YN’¦RƒIÃvÃ„Ç‹÷ ÷Õ÷èWÓ.à ÇÈà÷ ¼ûQO~xX‘J¼¢¿™Â‹Öàh=ûû",y- v÷İÇ÷ÇãĞ÷‹Ğ÷1ùÒêÜ„û*.l:BFüĞ÷İÄÍ©ˆ1³ğû€×û÷¢uº©S’á–ĞÇå÷:ÀûûH-„Ç÷ÜÇ÷`Ç{›ÂĞ÷ÎĞì÷«„÷#àé÷÷Aû¸/JLpPg‰÷"Ã÷+÷Iˆ³¹‚~¨‘Í,”ff’eû€<û>ûgìû8²û;÷M–øì¾N%-TD%$\âáçÆÊïœ v÷OÇøÍ˜ù˜ÎÖ÷O÷ôÖûOÓû©ùN=÷MüWûÃ÷,øü@ vùNwØĞØĞùNFœ v‹ßøšë‹wØĞøĞœØĞ¬øî÷ñüîèùNF\üú‰û÷øú4û*‹Ç÷¡Ç÷ÇáĞá÷öÇû±÷¡÷—Çû—÷÷¥Çûê-‹Ç÷¥Ç÷‰ÇÛĞ÷Ğ[ĞôÛ÷÷%÷º÷,çOÅ3›xáœ´Àä÷ ±ûû:ĞüÈôñö~ûû"r.CøÖêxÆè}&û*xB>‹ß÷êßíÜ`÷Gø’:7Ü :ü>Üß:—ùN—û\—÷x—÷©’ó“üø‘—ùN—û\—÷x—÷¨‘õ“üş—	Á
Ê
yXO	÷ªùendstream
endobj
42 0 obj
<<
/XHeight 762
/Ascent 750
/FontFile3 41 0 R
/StemV 63
/StemH 0
/ItalicAngle 0
/CapHeight 698
/FontName/ZTOKAW+Frutiger-Light
/Type/FontDescriptor
/Descent -210
/Flags 32
/FontBBox[-152 -250 1000 911]
>>
endobj
43 0 obj
<<
/Name/F18
/FontDescriptor 42 0 R
/Type/Font
/BaseFont/ZTOKAW+Frutiger-Light
/Widths[278 0 0 0 0 0 0 0 278 278 0 0 278 333 278 278 556 556 556 556 556 556 556 0 556 556 278 0 0 0 0 0 0 667 556 667 667 500 444 0 0 222 0 0 0 889 667 0 0 0 556 500 500 0 0 0 0 0 0 0 0 0 0 0 0 500 556 444 556 500 333 556 556 222 222 0 222 833 556 556 556 0 333 389 333 556 444 0 0 444 444 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 0 500 0 0 0 222 0 0 0 0 556]
/LastChar 151
/FirstChar 32
/Subtype/Type1
/Encoding 40 0 R
>>
endobj
44 0 obj
<<
/Differences[32/space 40/parenleft/parenright 47/slash 68/D/E/F 77/M/N 80/P 82/R/S/T 97/a 99/c/d/e/f/g 105/i 108/l/m/n/o/p 114/r/s/t/u/v 120/x 146/iacute 151/oacute]
/BaseEncoding/MacRomanEncoding
/Type/Encoding
>>
endobj
45 0 obj
<<
/Length1 2915
/Length 2915
/Subtype/Type1C
>>
stream
  ZYCDAX+Frutiger-LightItalic   Cø øøøøû#ûú›ú)
 ‹‹
 ‹‹  .  *  qÇ  ' •­µCopyright (c) 1988, 1990, 1994 Adobe Systems Incorporated.  All Rights Reserved.Frutiger is a trademark of Linotype-Hell AG and/or its subsidiaries.Frutiger 46 Light ItalicFrutiger     3 F G S O D J B 1 U T & E 4 Y P  	 .  ' 
 % H Ø / W M 5 N Q V Ó "   Z ¶Yµù&³ôF•Ê;”ÉK§ÕLÕ=z¡¹âiÙ	7	nü- v÷İÇ÷ÇøjĞ°ÑÑ÷İÜÃ£|T›Èû—ÏI÷ ±„°Q•÷âÏ÷÷:²ûˆû2ÁOğÒÂq<ûûk.Bû*Á÷WÁ÷EÁ²Ê÷ÒÊøp÷««ª÷OÕûû8'û/û?ûæD÷Ş²›–©Ècz]zL‹1JÃí™Œ™˜–ÁèœÓßíİ®T8‰~Š}ûÑ vø\Á÷ZÁ€–ÈøèÔÍíø\÷˜Áû“±œÜÚÖ‹©›ƒ‰šÀ`”ttsûlû3x€Xû~U÷ûÑ vø\ÁUÍ§÷óûÊĞ§Î¿÷(ç´÷òŠ„œšÎzzv‹I_dYk‰H¦«Lˆk†m…n- vøhµaÁ÷Ê÷ˆĞ¸§Í½÷†£÷	Æ÷÷‹Ë­eOi‡u„jQû­ÍÄ÷¡’«“±‹®ëG¿/LKhUh‰P¦«L‰r‡u…iûbÁø>Á²ĞøgøŠ•qN•aûY%ûûHûÒû÷'¿³’“£“Êk€e~e‹,EÚô÷Ùõ÷%³Æ~ü@ vø’w÷0ß§÷u.èğ§Í÷ ø’I(÷	÷p@y7Öû*Áaµ÷kÁ÷1ÁšĞ÷‡ÊĞºøH÷—”³°ŸõQÇûOQx|g„K­œÅ¦Æ‹Ñ²cEvŠ|‰|wtqûû<lû)7ÎPÚ„ÖÃ¢Ë¶D†u‰qˆpÊ®’º•²¨ûÙ–÷÷˜à Ÿ‰‹  }U!û
X[«Åû* v÷ÂÇ÷¨ÇølĞ÷ˆùÔÜÕx+û$a!=û(ûşĞÍ÷Âí÷÷Ò÷*÷'"§ûûûÑÁø2ÁæĞ÷Cø’'}UñZûv†uy:‹_T³cÒ¥”‘Áyz‡x‹fv¡³¬“¬’­Á÷÷˜Áûª÷Crû™Áø>ÁĞÍ÷Ğ}›w¼¹ƒÀîõ·÷÷û`–‹âÒÑ›½±µ€x¬ Æaœ`“]‹9 b&û÷]‹û<8tN`aš¡gû*‹Ç÷¡Ç÷Ç°ø|°÷ú•Çû³Ã÷¡÷š–Çû™¾÷÷©–Çûì-Áaµø>Á÷xw²Ğ÷œÌ˜vºøàù‚IEûâ‰ÑxL¯Aû6.ûBû"û½$÷„á¾±Â°D„w…jˆoÌ£‘®”´ªûîé÷
Ç÷0÷ãµD0û9û+û3fÎàû*ÇøîÇ÷Ğ÷PĞø›ù; ZU•PûûPûû5÷•‹û%û 'b-YQ›§bvIªzÁvæ‹÷÷×÷"÷Hû•˜‹÷éå¯Ø¼¼u¶ûb vø’wbø›bØ÷N÷lèûlÓû÷¡÷h÷…;û6ûR2÷RF÷û…-Áø>Á²Ğ÷ñĞ²÷fûÙ,÷÷Dö÷%÷>÷BâûûAûû!û?Ğ÷Í÷÷!î¶E+ûAû û2UÑã vùˆwÏÊ÷Şùˆûû4ûû4ûlû²ûºû¸a÷ q÷÷÷p÷÷A÷÷7÷ƒ v‹ßø¯Ö°ù÷°°Ë÷ù÷ıÄø"ùûıÏ÷(ùN püüúûøú+”vùfw…÷è…Î÷¥ùfFûb v÷İÇ÷Ç§øv§ĞÒ÷İ÷“—Çû”¾÷÷Ÿ˜Çûâ vùˆw÷OÊû ÷÷4÷÷4÷l÷d÷\÷^µû ¥ûûûpûûAûû7œ‹ÇøÖÇø×Ğ÷‡ùâ÷)ïKû0ûvûûûfû9O÷g÷“÷%÷=÷÷hû,ÏûOû-ûlÁ÷6Áø2µaÁ­Ğ÷Ü§Ü„ûJpÈÀ„Æ÷c°é÷E±×÷ó$•·”² Lhƒh…i‰ÜŞ{F¬;û>1û-û5ûÈ)÷ÏÅ£½¸ƒfmûdCû&‹TX–¬Yè÷Ú÷Í÷(÷è¸D0û	Jûû-aĞà-Áø>ÁÃ÷$²Ğ÷F÷8’Ğ÷;(÷øÖº÷	÷$<üıfÔ²÷fûÙ,÷÷Dö÷%÷>÷BâûûAûû!û?Ğ÷Í÷÷!î¶E+ûAû û2UÑãœ v‹ßø¦ß‹w§ù)˜§Ë ÷øú÷}üúİ÷(ùNLPûüú‰û}øú9ûb‹ĞøMwÌøAø‚ø’DûüM‰RøMKÏü’×ü@ vù‚w§÷v§Í÷4ù‚Iû* vùÇãøãù÷hûıÓ÷ù÷h—Çü÷K vøhµaÁ÷Ê÷mÇ÷Ğ¼§ÍÀ÷—çÀ÷	ó‹È£`Se…m„lRû¢ÍÀ÷—çÀ÷	ó‹È£`Se…m„lRû¢ÍÅ÷¨“°’²‹ŸèSÄ3:P`Dj‰ÕˆV³CEcrK[‰P¦«L‰p†i…r-ûQv÷ZÁø>µaÁ÷Ê÷œĞÜyûfÍÉ÷ÉE ÆbÓ÷@â÷>÷2÷PçûFKiUi‰h¥ªL‡eƒ`ƒe\¨ûO÷ Ô÷0÷ã¯G7û
Pû0ûh2dİÛ-ÁaµøhwÄĞ÷ˆÊ¸ø©ø’IYû†sû	Pûû‹Ki±Ç­¡’¬Å÷­IRû¡„kƒe‹h+ÏWçÊË®Á®H†yˆpˆkÊ¤¡‘­ü@ vø’wã÷$§÷B8÷8‹(÷øÖº÷	÷$<û`ıfĞ§Í÷ ø’I—ùN—û\—÷x—÷©’ó“üø‘—ùN—û\—÷x—÷¨‘õ“üş—	Á
Ğ
yXO	÷ªùendstream
endobj
46 0 obj
<<
/XHeight 762
/Ascent 750
/FontFile3 45 0 R
/StemV 69
/StemH 0
/ItalicAngle -12
/CapHeight 698
/FontName/ZYCDAX+Frutiger-LightItalic
/Type/FontDescriptor
/Descent -210
/Flags 96
/FontBBox[-143 -250 1031 917]
>>
endobj
47 0 obj
<<
/Name/F19
/FontDescriptor 46 0 R
/Type/Font
/BaseFont/ZYCDAX+Frutiger-LightItalic
/Widths[278 0 0 0 0 0 0 0 278 278 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 500 444 0 0 0 0 0 0 889 667 0 500 0 556 500 500 0 0 0 0 0 0 0 0 0 0 0 0 500 0 444 556 500 333 556 0 222 0 0 222 833 556 556 556 0 333 389 333 556 444 0 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 222 0 0 0 0 556]
/LastChar 151
/FirstChar 32
/Subtype/Type1
/Encoding 44 0 R
>>
endobj
48 0 obj
<<
/Count 4
/Type/Pages
/Kids[49 0 R 50 0 R 51 0 R 52 0 R]
>>
endobj
49 0 obj
<<
/Contents 1 0 R
/MediaBox[0 0 595.276 793.70099]
/Resources<</Font<<
/F5 31 0 R
/F0 11 0 R
/F4 27 0 R
/F2 19 0 R
/F3 23 0 R
/F6 35 0 R
/F1 15 0 R
>>
/ProcSet[/PDF/Text]/ExtGState<</GS2 3 0 R/GS0 2 0 R>>>>
/Type/Page
/Parent 48 0 R
>>
endobj
50 0 obj
<<
/Contents 4 0 R
/MediaBox[0 0 595.276 793.70099]
/Resources<</Font<</F0 11 0 R/F2 19 0 R>>/ProcSet[/PDF/Text]/ExtGState<</GS2 3 0 R/GS0 2 0 R>>>>
/Type/Page
/Parent 48 0 R
>>
endobj
51 0 obj
<<
/Contents 5 0 R
/MediaBox[0 0 595.276 793.70099]
/Resources<</Font<</F0 11 0 R/F18 43 0 R/F17 39 0 R/F19 47 0 R>>/ProcSet[/PDF/Text]/ExtGState<</GS2 3 0 R/GS0 2 0 R>>>>
/Type/Page
/Parent 48 0 R
>>
endobj
52 0 obj
<<
/Contents 6 0 R
/MediaBox[0 0 595.276 793.70099]
/Resources<</Font<</F0 11 0 R/F2 19 0 R>>/ProcSet[/PDF/Text]/ExtGState<</GS2 3 0 R/GS0 2 0 R>>>>
/Type/Page
/Parent 48 0 R
>>
endobj
53 0 obj
<<
/PageLabels 7 0 R
/Pages 48 0 R
/Type/Catalog
>>
endobj
54 0 obj
<<
/CreationDate(20050104074500)
/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)
/Producer(QuarkXPress(tm) 6.1)
/Creator(QuarkXPress(tm) 6.1)
>>
endobj
xref
0 55
0000000000 65535 f 
0000000015 00000 n 
0000010561 00000 n 
0000010625 00000 n 
0000010688 00000 n 
0000021171 00000 n 
0000031300 00000 n 
0000036380 00000 n 
0000036418 00000 n 
0000036890 00000 n 
0000046338 00000 n 
0000046555 00000 n 
0000047299 00000 n 
0000047465 00000 n 
0000050524 00000 n 
0000050756 00000 n 
0000051149 00000 n 
0000051379 00000 n 
0000057085 00000 n 
0000057310 00000 n 
0000057965 00000 n 
0000058385 00000 n 
0000068428 00000 n 
0000068648 00000 n 
0000069352 00000 n 
0000069477 00000 n 
0000070658 00000 n 
0000070885 00000 n 
0000071211 00000 n 
0000071455 00000 n 
0000076268 00000 n 
0000076489 00000 n 
0000076971 00000 n 
0000077116 00000 n 
0000079426 00000 n 
0000079646 00000 n 
0000080018 00000 n 
0000080142 00000 n 
0000080929 00000 n 
0000081154 00000 n 
0000081488 00000 n 
0000081824 00000 n 
0000086185 00000 n 
0000086406 00000 n 
0000086923 00000 n 
0000087157 00000 n 
0000090154 00000 n 
0000090383 00000 n 
0000090862 00000 n 
0000090940 00000 n 
0000091193 00000 n 
0000091387 00000 n 
0000091604 00000 n 
0000091798 00000 n 
0000091866 00000 n 
trailer
<<
/Size 55
/Root 53 0 R
/Info 54 0 R
/ID[<B7BC69F55575A8B6424F46812E5EAD43><B7BC69F55575A8B6424F46812E5EAD43>]
>>
startxref
92041
%%EOF
